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ABSTRACT 
 
Mucosal inflammation is a key feature in allergic rhinitis (AR) and chronic rhinosinusitis with 
nasal polyps (CRSwNP). The traditional idea of the epithelium as a simple barrier and 
neutrophils as a homogenous cell population, already terminally differentiated, has lately been 
reconsidered. Recent findings have identified advanced immunological properties of both 
epithelial cells (ECs) and neutrophil subsets. Toll-like receptors (TLRs) and activin receptor-
like kinases (ALKs) constitute important receptors of the ECs in recognizing stimuli leading to 
inflammatory and biological processes through altered gene expression. The new neutrophil 
classification, in four various subsets, is based on their expression of FcγRIII (CD16) and  
L-selectin (CD62L). The various subsets appear to have diverse roles during inflammatory 
conditions.  
The overall aim of this thesis is to investigate the role of the epithelial and neutrophil cells in 
upper airway innate immunity. 
Papers I-III explored the role of nasal epithelial cells (NECs) in antigen presentation as well as  
TLRs and ALKs on ECs in AR and CRSwNP. Major histocompatibility complex class II 
(MHC class II) as well as co-stimulatory molecules were found on NECs from mice and 
humans and were upregulated on OVA-sensitized mice. NECs from sensitized mice could take 
up, process and present antigens in a class II dependent manner for the activation of antigen-
specific CD4+ T cells. NECs from AR patients were able to activate autologous T cells against 
the major birch allergen protein, Bet v 1, and induce an IL-13 release. Normally, TLR9 can be 
found in NECs, but was found to be almost absent in NECs from the mucosa close to the polyps 
of CRSwNP patients. The TLR9 expression could be reconstituted by stimulation with its 
ligand, CpG, both in vitro and in vivo. Stimulation also resulted in a downregulation of 
VEGFR2, a receptor of angiogenesis, and cytokines. Investigation of polyp ECs revealed an 
upregulation of ALK1-6. Upon ligand stimulation, a downregulation of factors affecting cell 
proliferation (Ki67) and inflammation (ICAM-1 and IL-8) was seen. This was even more 
pronounced when microbial infection was mimicked.  
In Papers IV and V, neutrophil subsets were described for the first time in the nasal mucosa 
and a local shift to the activated subset became evident in AR and CRSwNP. In AR, the 
activated subset CD16high CD62Ldim was shown to have T cell priming capacities and an ability 
to enhance eosinophil migration. Neutrophils from CRSwNP patients displayed an 
upregulation of CD11b, most clearly emphasized on the cells of the activated subset. The 
corresponding adhesion molecule ICAM-1 was upregulated on the epithelium of polyps.  
In summary, epithelial and neutrophil cells in the nasal mucosa of patients with AR and 
CRSwNP exhibit an alerted receptor pattern with a deranged immunological response. 
Functional data including T cell activation, migration, adhesion and cytokine release clearly 
indicate a role for TLRs, ALKs and activated neutrophils in these upper airway inflammatory 
diseases. Further, antigen presenting ECs can contribute to mucosal inflammation in AR. 
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AIMS 
 
The overall aim of this thesis is to investigate the role of epithelial and neutrophil cells in upper 
airway innate immunity. More specifically to: 
 
- Determine if epithelial cells in upper airway inflammation demonstrate an altered 
receptor pattern in terms of antigen presentation as well as TLR and ALK expression 
(Papers I, II, III). 
 
- Investigate if stimulation of receptors linked to antigen presentation, TLRs and ALKs 
affect local nasal inflammation and cell proliferation (Papers I, II, III). 
 
- Explore whether neutrophil subsets are present in the nose and if there is a shift in 
neutrophil subsets during upper airway inflammation (Papers IV, V). 
 
- Analyze local innate mechanisms in relation to the epithelium and neutrophils in order 
to characterize their role in AR (Papers I, IV). 
 
- Assess whether local inflammation and disease progression in CRSwNP can be reduced 
by targeting TLRs, ALKs or activated neutrophils (Papers II, III, V). 
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INTRODUCTION 
 
The nose and paranasal sinuses 
The nose and paranasal sinuses represent the initial upper part if the airways, actively 
participating in airway dynamics. An adult inhales 10,000 liters of air every day, thus 
constantly exposing the upper airways to air-borne particles. A pseudo-stratified respiratory 
epithelium lines the mucosa and contains cells with both innate and acquired immune defense 
mechanisms. The nasal septum and the three turbinates separate the nasal cavity into different 
air chambers (Fig. 1).  
 
 
Figure 1. Schematic illustration of the nasal turbinates and the paranasal sinuses. The sphenoid and ethmoid 
sinuses are not visualized in this coronary projection. 
 
The paranasal sinuses are spaces within the bone that surround the nasal cavity and are 
normally air-filled. Four sets of paired sinuses are recognized: maxillary, sphenoid, ethmoid 
and frontal (Fig. 1). The paranasal sinuses maintain a near-sterile environment and lie in close 
proximity to the nasal cavity, being heavily colonized by myriads of potentially pathological 
microbes. In addition, particles attach to the nasal mucosa during normal breathing. These 
particles are removed by mucosal clearance, but the nose also actively participates in the 
immunological defense of the airways.1 Given these conditions, it seems remarkable that the 
mucosa of the nose and paranasal sinuses is in harmony and free from disease in most people. 
Epidemiological as well as clinical studies have highlighted the relationship between the upper 
and lower airways. Up to 60-78 % of patients with asthma also have co-existing allergic rhinitis 
(AR), leading to the concept of “United Airways” or “Unified Airways”.2, 3 Likewise, 40-75 % 
of all patients with asthma have concurrent chronic rhinosinusitis (CRS).4 Interestingly, the 
association with asthma was even stronger in those patients reporting both CRS and AR.5  
A considerable overlap between asthma and sinonasal comorbidities thus confirm the concept 
of “United Airways”. 
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UPPER AIRWAY DISEASE  
Allergic rhinitis   
AR is an inflammatory disease of the sinonasal mucosa, induced by a reaction to a normally 
harmless antigen. It has troublesome local symptoms such as itching, sneezing, nasal drip and 
obstruction, resulting in negative impact on quality of life in combination with fatigue.6 
Relatively often, the disease is complicated by asthma and co-existing sinusitis, conjunctivitis 
and skin manifestations. The diagnosis AR is based on clinical history combined with positive 
skin prick test and/or radioallergosorbent test (RAST). A positive skin prick test is revealed by 
a skin reaction within 15 minutes. RAST detects allergen-specific IgE in serum towards the 
specific airborne allergen tested. The allergen is added to the patient’s serum and after washing 
procedures, polyclonal anti-human IgE is added and if sufficiently bound, the test result turns 
positive (Fig. 2). 
 
 
Figure 2. RAST for allergen-specific IgE in serum. Allergen-specific IgE in red, non-specific IgE in green and 
labeled IgE in blue highlighted with yellow stars. 
 
Previously, AR was considered a relatively rare disease. However, during the last 100 years, 
the incidence in most industrialized countries has increased. Several hypotheses have been 
proposed to explain this increase among which the hygiene hypothesis has some strong 
spokesmen.7, 8 According to this theory, changes in lifestyle in industrialized countries have led 
to a lower infectious burden but instead, a rise in both allergic and autoimmune diseases. Today, 
AR causes major medical and socioeconomic problems, affecting up to 40 % of children and 
10-30 % of adults in industrialized countries.9 In Sweden, rhinitis cost 2.7 billion euro a year 
due to lost productivity, according to a questionnaire-based study.10, 11 
Allergic immune responses  
The allergic inflammatory response can be divided into two main phases: the initial 
sensitization phase and the subsequent effector phase. In the sensitization phase, an atopic 
individual is exposed to an allergen promoting activation of allergen-specific T helper (Th) 2 
cells which secrete cytokines (for example interleukin (IL)-4, IL-5 and IL-13) thus inducing 
IgE-production by B cells. These IgE molecules then bind to the surfaces of mast cells and 
basophils in a process known as sensitization. Upon re-exposure to the allergen, the effector 
phase takes place. Cross-linkage of the IgEs leads to degranulation and release of inflammatory 
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mediators including cytokines and histamine. These mediators affect vascular permeability and 
may cause smooth muscle contraction. In addition, they recruit eosinophils, neutrophils and 
Th2 T cells, causing the late phase reactions. 
Chronic rhinosinusitis 
CRS is a disease defined as chronic inflammation of the nose and paranasal sinuses. It is 
characterized clinically by symptoms like nasal congestion or discharge, loss of smell, facial 
blockage and pain causing considerable morbidity lasting for 12 weeks or longer. The diagnosis 
CRS is verified by endoscopic examination (Fig. 3) and computed tomography (CT) changes 
(Fig. 4) according to the EPOS guidelines.1 CRS can be divided into CRS with and without 
nasal polyps (CRSwNP and CRSsNP). In CRSwNP, nasal polyps are visualized by anterior 
rhinoscopy or endoscopic examination. Recent data indicates that CRS affects 5-15 % of the 
population in Europe and in the US. The same increasing trend is seen for allergy, and CRS 
 
  
 
Figure 3. Endoscopic examination of the nose. (A) Right and (B) left nostril of healthy control without polyps. 
(C-D) Left nostril of two different CRSwNP patients. NS = nasal septum, NP = nasal polyp, IT = inferior turbinate, 
MT = middle turbinate. 
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Figure 4. CT scan of the sinuses. (A-B) Healthy control and (C-E) three different CRSwNP patients. The patients 
display different grades of sinus obstruction and opacification, seen as grey instead of black color. F = frontal 
sinus, E = ethmoid sinus, M = maxillary sinus, * = partial or total opacification of the sinus.   
 
together with allergy are hence frequently associated.12 CRSwNP and asthma are also 
associated, albeit their inter-relationship remains poorly understood.6 Patients suffering from 
CRSwNP, asthma and aspirin sensitivity at the same time (termed ‘Samter’s triad’) constitute 
a selected group of patients and often suffers more severe disease.1 The majority of patients 
with CRS can be successfully treated with topical corticosteroids, at least during the first years 
of disease. Occasionally, oral corticosteroids or antibiotics can be required periodically. In 
addition, a small group of patients require surgery. Functional endoscopic sinus surgery (FESS) 
involves the removal of polyps and affected polypoid mucosa as well as opening of the sinuses. 
The clearance of inflammatory tissue, as well as the improvement of sinus ventilation, are the 
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probable successful mechanisms of FESS. The rate of relapse in CRS symptoms after surgery 
tends although to be higher for patients with compared to without nasal polyps.13  
The etiology behind CRSwNP is probably multifactorial, including genetic factors, anatomical 
circumstances, infections and local inflammatory impairment. It is unknown why some people 
develop polyps and some do not. A well-documented clinical observation is however that an 
upper airway infection often precedes the polyp development.14 The nasal polyps arise from 
the mucosa in the sinuses or in the nose. The benign masses consist of loose connective tissue, 
pronounced edema, inflammatory cell infiltration, and capillaries and glands. Eosinophils are 
the most frequent inflammatory cells in nasal polyps, leading to large concentrations of IL-5.15 
The inflammation seen in Western countries is most often characterized by a robust Th2 
response.16, 17 The development of new monoclonal antibodies like anti-IgE and anti-IL-5 has 
thus opened up the possibility of a new treatment arsenal in CRSwNP. However, current data 
yield insufficient evidence to recommend either of them for medical treatment of CRSwNP, 
especially non Th2 CRSwNP or Asian patients biased towards neutrophilic inflammation.17 
Ongoing investigations may though clarify this matter in the near future.1, 18 Finally, several 
publications have established that CRS consists of numerous endotypic clusters highly 
correlating with phenotypic parameters. This indicates that CRS is a more complex 
immunological disease than previously thought, warranting more personalized treatment 
strategies.16, 19 
 
THE IMMUNE SYSTEM  
The immune system comprises a collection of tissues, cells and molecules that mediate 
resistance to potentially harmful substances and pathogens. Host defense mechanisms consists 
of the innate immune system, which mediates the initial rapid protection against pathogens, 
and the adaptive immune system, which develops more slowly and mediates a more effective 
and specific defense. These two branches of the immune system have traditionally been 
described as separate systems. Accumulating evidence has however proven close interactions 
between the two arms, establishing the view that efficient protections against pathogens is 
mediated by a tight cooperation between these arms, making strict sectioning an incorrect 
simplification.20 
The immune system is required for eliminating foreign structures. However, immune responses 
are capable of causing tissue damage and disease. Hypersensitivity, for instance, is a reflection 
of an excessive or aberrant immune response to an antigen instead of a normal, balanced 
response. Another example of misdirected immune response is autoimmune disease, where the 
immune system is directed against self (autologous) antigens, as a result of the failure of self-
tolerance. 
Innate immunity  
All individuals are provided with an innate immunity. The skin and the mucosa create a 
physical barrier that constitutes the first line of the innate immune system. The cellular, second 
innate line of defense, is primarily facilitated through the actions of monocytes, macrophages, 
granulocytes (neutrophils, eosinophils and basophils) and dendritic cells (DCs) and becomes 
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activated if the pathogen circumvents this initial defense. The innate immune system is 
characterized by its rapid action and it does not adapt to the presence of microbial agents like 
the adaptive immune system. 
To be able to respond immediately to invading pathogens, innate immune cells express 
germline-encoded receptors called pattern-recognition receptors (PRRs). They are found on the 
cell membrane, in the endosomal compartments and in the cytosol. PRRs recognize and bind 
to conserved microbial components termed pathogen-associated molecular patterns (PAMPs). 
The human PRR family consists of at least three receptor families, including toll-like receptors 
(TLRs), NOD-like receptors (NLRs) and RIG-like receptors (RLRs). The TLRs are the most 
well-known group of PRRs and they are essential for innate and adaptive immune responses. 
Ten different TLRs are known in humans, each recognizing a specific pathogen pattern.21 TLRs 
have been demonstrated in various cells and tissues, including eosinophils, neutrophils, DCs, 
lymphocytes, nasal mucosa and tonsils.22-25 
 
 
Figure 5. Key events during the interaction between an antigen presenting cell (APC) and a T cell. An antigen 
(PAMP) binds to a TLR on an APC, whereupon the antigen is endocytosed and processed into peptides. The 
peptide binds to a MHC class II molecule intracellularly and the complex is subsequently transported to the cell 
membrane, where the peptide is presented to a T cell. Full T cell activation further requires interaction of co-
stimulatory molecules and cytokine signaling.  
 
Adaptive immunity  
The adaptive immune system is based on lymphocytes named T and B cells and is initiated 
when their receptors recognize antigens. Lymphocytes have a vast receptor diversity enabled 
through somatic recombination during cell development, meaning that lymphocytes can mount 
specific responses towards infectious agents. Hence, adaptive immunity is more specialized 
than the innate system and is able to combat infections that have evolved to evade innate 
responses. This system is also responsible for the generation of our immunological memory.  
T and B cells circulate in their naïve forms in blood and lymphoid tissues until they are 
activated by antigen presenting cells (APCs) like DCs. The APCs display peptides through 
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major histocompatibility complex class II (MHC class II) molecules as well as co-stimulatory 
molecules (Fig. 5). The MHC molecules in humans are called human leukocyte antigens 
(HLAs). There are different sets of class II genes, and HLA-DR constitutes one of them. Upon 
activation, B cells differentiate into plasma cells which secrete antibodies, or memory cells. 
The T cells can be divided into several categories, for instance into Th cells being CD4+ and  
T cytotoxic (Tc) cells being CD8+. The naïve Th cells are activated to differentiate into for 
example Th1, Th2 and Th17 cells, which display different patterns of cytokine secretion. While 
Th1 cells primary secrete interferon gamma (IFN-γ), the Th2 cells secrete IL-4, IL-5, IL-6,  
IL-9 and IL-13. Th17 cells produce IL-17. Allergy and CRSwNP are often characterized by 
Th2-biased inflammation. 
 
LINKS BETWEEN INNATE IMMUNITY AND UPPER AIRWAY INFLAMMATION  
Epithelial cells  
Nasal epithelial cells (NECs) constitute a physical barrier but also play an active role in innate 
and adaptive immune responses.26 TLRs have been identified on airway epithelial cells 
(ECs).27-29 ECs of CRSwNP patients have been shown to secrete more GM-CSF, eotaxins and 
RANTES than healthy controls, potentially contributing to the recruitment and survival of 
eosinophils.30-33 Furthermore, ECs can secrete TSLP, IL-33 and IL-25 affecting Th2 
inflammation mainly through DCs and innate lymphoid cells.34 
 
Figure 6. Epithelial cells. (A) Immunofluorescent image of epithelial cells from human nasal mucosa expressing 
MHC class II molecules (green). Scale bar: 50 µm. (B) A schematic and simplified figure of antigen presentation 
by the epithelium. Antigens (PAMPs) bind to PRRs on an epithelial cell and are degraded into peptides 
intracellularly. Subsequently, the peptides are presented in a class II dependent manner to a T cell. 
 
A B
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The ability to recognize and react to foreign antigens and thereafter activate the adaptive 
immune system has traditionally been assigned to APCs like DCs, macrophages and certain  
B cells. At homeostasis, MHC class II expression is restricted to these professional APCs, 
whereas MHC class I molecules are expressed on all nucleated cells. However, during 
inflammation, ectopic expression of MHC class II can be detected on other cells than 
professional APCs, and from multiple tissues including esophagus, intestine, kidney, skin and 
airways (Fig. 6A).35-40 ECs have thus been suggested to have more complex features than being 
a barrier, producing mucous, having cilia activity and releasing cytokines. Just like traditional 
APCs, ECs express MHC class II molecules on their surface, crucial for antigen presentation 
to CD4+ T cells. 41-43 These findings suggest an antigen-presenting potential of ECs (Fig. 6B), 
although the molecular mechanisms and immunological importance of this function have not 
yet been fully examined. 
Neutrophils  
Neutrophils have a key role in eliminating invading pathogens and in promoting tissue repair, 
and are thus essential for the innate immune response. Neutrophils are the most abundant 
leukocyte in human blood and in response to infections, the production of neutrophils from the 
bone marrow increases rapidly. Upon infection, an upregulation of adhesion molecules on the 
endothelium of the blood vessel will start a process of neutrophil extravasation. Their half-life 
in blood is normally relatively short (6-8 hours) but upon migration to inflamed tissue where 
they phagocytose and kill bacteria, their survival has been shown to be extended.44 After killing 
bacteria, the neutrophils undergo apoptosis and are cleared by resident macrophages. Lately, 
neutrophils have however been demonstrated to have functions beyond the role of killing 
bacteria. The idea of neutrophils as homogenous, short-lived cells already terminally 
differentiated has been challenged. Attention has recently been paid to the findings of different 
neutrophil subsets defined by differences in FcγRIII (CD16) and L-selectin (CD62L) 
expression.45, 46 This has resulted in the defining of four different subsets: CD16dim CD62Lhigh  
 
Figure 7. A schematic figure illustrating the maturation or activation process of neutrophils on a flow cytometry 
dot plot. Immature neutrophils derived from the bone marrow (CD16dim CD62Lhigh) express CD62L but hardly 
CD16 and are displayed in the upper left quadrant. Normal mature neutrophils (CD16high CD62Lhigh) express both 
CD16 and CD62L and are localized in the upper right quadrant. Activated neutrophils (CD16high CD62Ldim) 
express CD16 but have lost the CD62L molecules and are found in the lower right quadrant. End state  
CD16dim CD62Ldim neutrophils are displayed in the lower left quadrant. 
C
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(with banded nuclear morphology, characteristic of neutrophils derived from the bone marrow 
and hence considered to be a less mature subset), CD16high CD62Lhigh (phenotypically normal 
mature neutrophils), CD16high CD62Ldim (with a hyper-segmented nucleus, thought to be 
activated) and CD16dim CD62Ldim (not further defined) (Fig. 7). 
Eosinophils play an important inflammatory role in airway allergy and CRSwNP. Neutrophils, 
are at the same time known to increase in allergy.47, 48 Their relative increase is not as distinct 
as the one of eosinophils, but their absolute increase deserves certain attention. At the same 
time, significant numbers of neutrophils accumulate in the nasal mucosa of CRSwNP patients, 
and the Asian CRSwNP-population is even biased towards neutrophilic inflammation.17 Their 
contribution to CRSwNP pathogenesis has so far been unclear. However, the recent reports on 
different neutrophil subsets, all with diverse roles during inflammatory conditions, raises the 
question whether these subsets are present in, and affect the course of, upper airway 
inflammation. 
Toll-like receptors  
During the last decade, opinion has shifted from considering CRS to have an underlying 
infectious cause to view it as a disease of constant inflammation.41 The discovery of TLRs as 
a part of the innate immune system more than 30 years ago has opened possibilities for 
exploring the underlying mechanisms of this opinion (Fig. 8). At the same time, increasing 
evidence indicate that TLRs also are linked to allergy.  
 
 
Figure 8. TLRs (red and yellow). TLR1, 2, 4-6 and 11 bind to the cell surface while TLR3 and 7-9 act 
intracellularly. The TLRs bind ligands derived from viruses, bacteria and fungi. Upon binding, an intracellular 
signal cascade results in altered transcription of DNA, resulting in immune events. 
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Nasal TLR expression25, 49 and the effects of local treatment with TLR8 agonist50 has recently 
been studied among patients with AR, suggesting that TLRs have a role in allergic airway 
inflammation. We have demonstrated the presence of TLR2, 3 and 4 both in mRNA and as 
proteins in nasal mucosa, and an increase in protein expression has been seen following 
allergen challenge.49 A dysregulation of TLR9 genes has been shown among patients with 
CRSwNP.51, 52 TLR9 seem to induce a Th1-biased immune response, known to suppress Th2-
inflammation often seen in CRSwNP.53 We have previously detected the expression of TLR9 
in healthy nasal mucosa.54 Cytosine phosphate-guanine oligodeoxynucleotide (CpG-ODN) is 
a TLR9 ligand found in viral and bacterial DNA. The ability of CpG to induce Th1-related 
activities has made it an interesting potential target for the treatment of allergy and 
inflammatory diseases caused by microbes.55, 56 
Activin receptor-like kinases  
The transforming growth factor beta (TGF-β) superfamily consists of more than 30 different 
ligands in mammals and have been conserved through evolution.57 They are involved in a range 
of biological processes, and can be divided into TGF-βs, activins, bone morphogenetic proteins 
(BMPs) and growth differentiation factors (GDFs). The TGF-β ligands act through type I 
transmembrane serine/threonine kinase receptors, also termed activin receptor-like kinases 
(ALKs), and type II transmembrane serine/threonine kinase receptors.58 So far, seven ALKs 
have been described in mammals.59  
Ligands can bind multiple ALKs but their affinities vary greatly.60-62 Upon binding, a number 
of intracellular SMADs are activated through phosphorylation, eventually regulating gene 
expression (Fig. 9). Disruption in the pathway linked to the TGF-β superfamily has been linked 
to various diseases, including airway inflammation.58, 63, 64 
 
Figure 9. ALKs (blue), illustrated on the cell surface. ALK ligands (purple) can bind multiple ALKs, illustrated 
in the picture. ALK-ligand interaction causes phosphorylation (yellow P) of intracellular SMADs and regulates 
gene expression in the nucleus resulting in for example immune events. 
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MATERIALS AND METHODS 
 
This section contains a brief overview of the materials and methods used in the studies. More 
details can be found in the individual Papers I-V. 
Human study population 
CRSwNP patients in Papers II, III and V were defined by EPOS criteria [European Position 
Paper on Rhinosinusitis and Nasal Polyps] based on symptoms, results of nasal endoscopy and 
CT of the sinuses.1  
AR patients in Paper I and IV were diagnosed based on clinical history and positive skin prick 
test and/or positive RAST for the relevant allergen (phadiatop was used, detecting IgE against 
birch, timothy, mold, mugwort, mite, cat, horse and dog and in addition Bet v 1 in Paper I).  
Healthy controls in Papers I-V had no history of sinus disease, asthma or allergy. None of the 
healthy controls were pregnant, had a history of steroid use, had a positive skin prick test/RAST 
upon testing or were smokers.  
Human characteristics and samples obtained (defined in brackets) of each Paper:  
Paper I: Patients with AR (nasal brushing and peripheral blood) and healthy controls (nasal 
brushing or nasal biopsies and peripheral blood). 
Paper II: Patients with CRSwNP (biopsies of turbinate tissue, polyps and peripheral blood) and 
healthy controls (nasal biopsies and peripheral blood).  
Paper III: Patients with CRSwNP and healthy controls (nasal biopsies and/or nasal brushing 
and peripheral blood).  
Paper IV: Patients with AR and healthy controls (nasal biopsies, nasal lavage (NAL) and 
peripheral blood).  
Paper V: Patients with CRSwNP (biopsies of turbinate tissue, polyps and peripheral blood) and 
healthy controls (nasal biopsies and peripheral blood).  
All studies were performed at the ENT department at Karolinska Institutet or Karolinska 
University Hospital in Stockholm. Fresh human materials were used in all studies after 
approval from the Ethical Review Board at Karolinska Institutet or Lund University and an 
informed consent was obtained from all participants.  
Animals 
In Paper II, cells from C57BL/6 and OT-II T cell receptor (TCR) transgenic mice were used. 
The animals were supplied with pelleted food and water ad libitum and were housed in a 
climate-controlled environment with a 12 hours daylight cycle. C57BL/6 mice were sensitized 
by means of intraperitoneal injection of grade V ovalbumin (OVA) and aluminium hydroxide 
administered in the morning on days 0 and 7. The study was approved by the Swedish Animal 
Experimental Review Board.  
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Human nasal samples 
Biopsies from non-polypoid turbinate tissue (inferior or middle) and polyps were taken during 
FESS or in local anesthesia from patients with CRSwNP. Biopsies from inferior turbinates of 
healthy controls were taken after topical application of local anesthesia. Tissue used in Papers 
I, II, IV and V was filtered through a cell strainer into Nutrient Mixture Ham F12 medium 
(DMEM/F-12) containing serum. Cells were washed and centrifuged and the supernatant was 
subsequently aspirated and discarded. The cells were stained and analyzed with flow 
cytometry. 
Nasal brushing was performed using a cytology brush to obtain NECs from the middle meatus. 
Cells were stained and analyzed immediately with flow cytometry or cultured in collagen-
coated tissue culture flasks. 
NAL fluid was collected by first cleaning excess mucous by forceful exsufflation and 8–10 ml 
of sterile saline solution was then sprayed into the nostrils and passively collected when 
dripping out. Cells were stained and analyzed with flow cytometry.   
Human nasal challenge 
In Paper I, CRSwNP patients were intra-nasally challenged with a spray containing 
physiological saline solution and 50 mM CpG-ODN or saline solution (placebo). Nasal 
biopsies and peripheral blood were obtained during FESS the following day and stained and 
analyzed with flow cytometry. The patients and the person analyzing the samples were blinded 
regarding which spray that had been used. 
Stimulation and co-cultures of tissues and cells 
In Paper II, human nasal biopsies were used for in vitro experiments to determine whether CpG 
stimulation had an impact on TLR9 and vascular endothelial growth factor receptor 2 
(VEGFR2) expression as well as cytokine release. Tissues were separated into pieces of  
0.05 g and incubated on 24-well culture plates in DMEM/F-12 with serum, penicillin, 
streptomycin and fungizone. The biopsies were subsequently stimulated with modified CpG-
ODN for 4 or 24 hours. Cells were stained and analyzed with flow cytometry and supernatants 
were analyzed with Luminex. 
Primary human NECs (HNECs) obtained by nasal brushing were cultured for experiments in 
Papers I and III. Cells were maintained in collagen-coated tissue culture flasks in Keratinocyte 
Serum-Free Medium (KSFM) containing epidermal growth factor, bovine pituitary extract, 
penicillin and streptomycin. Fungizone was in addition added to the cells stimulated with Bet 
v 1 in Paper I and to all cells in Paper III. Cultured cells were used in passage 2-6 for the 
experiments. They were positive for the epithelial cell adhesion molecule EpCAM.  
In Paper I, the cultured HNECs were subsequently used for co-cultures to determine whether 
the epithelium could present antigens to T cells and cause cell activation and proliferation. 
Autologous T cells were isolated from peripheral human blood using negative selecting 
magnetic antibody cell sorting separation. By adding magnetic labelled antibodies and placing 
the tube with blood in the magnetic field, the magnetically labeled cells adhered to the wall of 
the tube. The supernatant, containing the T cells, could then be collected. Residual erythrocytes 
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were depleted. Cultured HNECs were then stimulated with birch pollen extract or Bet v 1 for 
24 hours. Upon washing, T cells were added and re-suspended in TexMacs-medium containing 
L-glutamine, serum, penicillin, streptomycin and fungizone. Upon 4, 24 or 48 hours of co-
culture, T cells and HNECs were collected, stained and analyzed with flow cytometry while 
supernatants were analyzed with Luminex.  
In Paper III, cultured HNECs were used to see whether stimulation with ALK ligands could 
impact on factors linked to cell proliferation and/or inflammation. Cultured NECs were 
stimulated for 24 hours with either TGF-β1, Activin A, BMP4 or Activin B. In separate 
experiments, tumor necrosis factor α (TNF-α) was added the last 4 hours to mimic microbial 
load. Cells were then stained and analyzed with flow cytometry and supernatants were analyzed 
with enzyme-linked immunosorbent assay (ELISA). 
In Paper IV, human co-cultures with neutrophils and T cells or neutrophils and eosinophils 
were set up to establish whether activated neutrophils could prime T cells and/or cause 
eosinophil migration. Peripheral blood was collected in heparin tubes and neutrophils and  
T cells or eosinophils were isolated using ficoll-paque and additional positive selection using 
CD15 microbeads further purifying neutrophils, or MACSxpress Isolation Kits for negative 
selection of neutrophils and eosinophils. Remaining erythrocytes were lysed. Neutrophils were 
diluted in RPMI-medium containing autologous plasma, penicillin and streptomycin and 
subsequently activated with 1 μg/ml lipopolysaccharide (LPS), 5 ng/ml TNF-α and 10 ng/ml 
IL-8 and then washed. For T cell assays, a co-culture with activated neutrophils and 
lymphocytes was set up in wells for 30 minutes and CD3 was subsequently added for  
90 minutes for T cell activation. Transwell plates were used to block cell-cell contact in 
separate experiments, adding CD3 to the lymphocyte part of the transwell plates. For eosinophil 
assays, migration set up was conducted with transwell plates for all experiments. Neutrophils 
were added to the bottom well and eosinophils were added to the insert. After 3 hours of 
incubation, inserts were removed and cell suspensions were collected. Cell suspensions of both 
T cell and eosinophil assays were subsequently stained and analyzed with flow cytometry. 
In Paper I, mouse nasal epithelial cells (MNECs) were cultured to see if they could act as APCs. 
The use of mouse cells made it possible to use a transgenic system (OT-II mice) as well as to 
use naïve T cells as reporter cells, two settings not viable in a human setting. Mice septal 
mucosa were isolated from nasal septums as previously described 65 and put in DMEM/F-12 
and then into dissociation medium for 1 hour containing minimal essential medium, 
penicillin/streptomycin, pronase and DNase. DMEM/F12 containing FBS was added to stop 
the reaction. Tissue was filtered through a cell strainer and thereafter cultured in complete 
culture medium with DMEM/F12 containing penicillin/streptomycin, FBS and ITS Premix. 
The suspension was incubated for 2 hours on culture dishes to let fibroblasts adhere. 
Supernatants containing ECs were then collected and cultured in collagen-coated tissue culture 
dishes containing complete culture medium. To obtain mouse T cells, spleens were taken from 
mice, filtered through a cell strainer and then washed and centrifuged. The supernatant was 
discarded and remaining splenic cells were added to ECs stimulated with OVA for 4 or  
24 hours. In separate experiments, anti–MHC class II antibodies were added. 
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Immunohistochemistry 
Optical imaging in Papers I and III was carried out using classic immunohistochemistry (IHC) 
or immunofluorescence (IF). In IHC, a primary and secondary antibody is added and 
visualization is subsequently accomplished using a chemical reaction to produce a color 
change. In IF, the target is detected using an antibody and subsequent visualization is made by 
adding a fluorophore coupled to the secondary antibody. 
In Paper I, cultured HNECs from an AR patient were pre-incubated with serum to block non-
specific binding and subsequently incubated with an anti–MHC class II primary antibody 
followed by a fluorescein-coupled secondary antibody to visualize MHC class II expression. 
Imaging was performed with a Nikon Digital Sight DS-U1 camera coupled to a Nikon Eclipse 
TE2000-U microscope. 
HNECs from another AR patient in Paper I were used to study antigen uptake. Fluorescein 
coupled to dextran was added to HNECs in complete medium and thereafter washed with PBS 
to visualize endocytosis. Cells were fixed in formaldehyde, washed with PBS and subsequently 
incubated with serum to block non-specific binding. MHC class II expression was visualized 
with an anti–MHC class II primary antibody followed by a fluorescein coupled secondary 
antibody. Stained cells were maintained in anti-fade reagent with 49-6-diamidino-2-
phenylindole (DAPI) to visualize nuclei. For laser confocal microscopy, a Nikon Eclipse TE 
300 microscope equipped with a solid-state laser and connected to a Hamamatsu ORCAER 
camera was used.  
In Paper III, nasal biopsies were fixed and embedded in paraffin and subsequently cut into  
5 μm sections. Sections were deparaffinized, rehydrated and incubated in Sudan black B (for 
DAB staining) in 70 % ethanol. Following antigen retrieval in citrate buffer, sections were 
permeabilized. For 3,3’-diaminobenzidine (DAB) staining, inhibition of the endogenous 
peroxidase activity was accomplished by treating the tissues with 1 % H2O2 followed by 
incubation with serum and bovine serum albumin (BSA), blocking non-specific binding. For 
IF, BSA was used to block non-specific binding. Sections were incubated with a primary 
antibody against IL-8, Ki67, intercellular adhesion molecule 1 (ICAM-1), ALK2, ALK3, 
ALK5, ALK7 or EpCAM and subsequently incubated with a secondary antibody. Sections for 
DAB staining were incubated with Avidin-Biotin-Complex followed by DAB and 
counterstained with Mayer’s Haematoxylin. For IF, mouse antibody diluent was used as a 
negative control. For DAB staining, images were captured with a Nikon Digital Sight DS-U1 
camera, coupled to a Nikon Eclipse TE2000-U microscope. For IF, imaging was performed 
using an Olympus Provis microscope, connected to an Olympus U-PS camera.  
Flow cytometry 
Flow cytometry was the main method used in Papers I-V. The method analyzes the physical 
and chemical properties of individual cells in a suspension based on how they scatter light from 
a laser beam. Using different detectors, the flow cytometer is able to provide information about 
cell size (displayed as forward scatter, FSC), granularity (displayed by side scatter, SSC) and 
fluorescence intensity of fluorochrome-conjugated antibodies used for detection of intra- or 
extracellular antigens. Flow cytometry thus allows simultaneously multi-parametric analyses 
of both physical and chemical characteristics of up to thousands cells per second. The data can 
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then be plotted as a single dimension on a histogram (Fig. 10A) or in a two-dimensional dot 
plot (Fig. 10B-C). The dot plot reveals correlations between two different parameters, 
characterized on the x- and y-axis. The regions on this plot can be separated based on 
fluorescence intensity, a process called ‘gating’ (Fig. 10C). The cells in this gate can be further 
plotted on a new dot plot, with two new parameters. The cells of a gate (often referred to as a 
‘population’) can be presented in different ways: for example in relation to all cells, in relation 
to a specific group of cells (leukocytes for instance), in absolute count or as mean fluorescent 
intensity (MFI).  
 
 
Figure 10. Flow cytometry data of blood from an AR patient. (A) A histogram demonstrating CD11b positive 
cells (open histogram, black line) and negative isotype control (filled histogram, black line). (B) A dot plot 
demonstrating the FSC and SSC of cells in blood. Roughly, the top population (high FSC and SSC) comprises of 
granulocytes, the bottom right population (high FSC, low SSC) comprises mainly of lymphocytes and monocytes 
and the bottom left population (low FSC and SSC) comprises of erythrocytes, thrombocytes and dead cells.  
(C) A dot plot displaying neutrophils based on their expression of CD16 and CD62L. The lines constitute gates, 
separating the cells into four different subsets (fractions displayed in % below ‘Q1-Q4’). 
 
The intensity read out in flow cytometry is relative and user-adjustable. Hence, unstained or 
negative controls are needed. Three major issues always have to be taken into account in flow 
cytometry. Unstained cells emit background fluorescence (called autofluorescence), 
determined by also analyzing unstained cells. Antibody-antigen interactions can be non-
specific: antibodies bind non-specifically to Fc receptors on the surface of many cells and dead 
cells tend to soak up antibodies. With a correct control, called isotype control, using the same 
monoclonal antibody but with an irrelevant specificity, this problem can be solved. 
Alternatively, or in addition, an Fc block can be used. Finally, the emission spectra of different 
fluorescent dyes overlap and hence, a dual color analysis can result in signals on both 
fluorescence detectors even for cells which only carry either of the fluorochromes. This is 
especially a problem in multi-parametric flow cytometry and is solved with compensation.  
A fluorescence minus one (FMO) control is used, containing all the fluorochromes in a panel 
except for the one that is being measured. This results in preferences used when defining 
positive and negative signals. Last but not least, a positive control is desirable to prove that the 
test antibody is functional and to allow proper settings of the flow cytometer.  
Peripheral blood in the Papers was always lysed prior to staining. Staining was performed with 
antibodies conjugated with fluorochromes. Samples were fixed prior to analysis and an 
LRSFortessa analyzer and data were processed using FlowJo software. 
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Enzyme-linked immunosorbent assay 
ELISA is a method for detection and quantification of an antibody or an antigen in a sample. 
The method was used in Paper I to detect secreted IFN-γ in supernatants of mouse co-cultures 
and in Paper III to detect secreted IL-8 in supernatants of stimulation assays. Sandwich-ELISAs 
were used based on microplates pre-coated with antibodies against the antigen of interest. 
When adding a sample to the microplate, potential antigens in the sample will bind to the 
antibodies. After washing away unbound substances, an enzyme-linked polyclonal antibody 
specific for the antigen of interest was added and upon adding a substrate solution, a color 
developed in proportion to the amount of bound substrate.  
Luminex 
Luminex multiplex immunoassay is a method that quantifies several proteins or peptides at the 
same time in one sample. The method was used to detect cytokines in the supernatants of the 
human co-cultures in Paper I and in the human CpG stimulation assays in Paper II. Luminex 
has generally lower detection levels than ELISA but can be more expensive, depending on how 
many cytokines that are of interest. Luminex is similar to sandwich-ELISA, with the exception 
that magnetic beads dyed with fluorescent dyes are covalently coupled to the antibodies 
directed against the antigen of interest. Each bead thus has a distinct color code permitting 
discrimination of individual antigens. Human Cytokine Standard 17-plex were used in both 
Papers I and II and subsequently quantified on the Luminex200 system. 
Statistical analyses  
Statistical analyses were performed using GraphPad Prism software. In all Papers, mean is 
represented by a horizontal line for data presented as individual values. Remaining data is 
represented as mean ± standard error of the mean (SEM). A p-value of 0.05 or less was 
considered statistically significant (*p < 0.05; **p < 0.01 and ***p < 0.001) and n equals the 
number of included subjects. 
An unpaired t-test was used to compare two sets of data. For non-repeated measurements, a 
one-way analysis of variance (ANOVA) with a Bonferroni (Paper I) or a Tukey (Paper IV) 
post-test was performed. Non-parametric data were analyzed with a Kruskal-Wallis (Papers II 
and V) or a Friedman test (Papers III and IV) test together with a Dunn’s multiple comparisons 
post-test (for more than two sets of paired data) except for the eosinophil migration experiments 
in Paper IV where a Tukey’s multiple comparisons post-test was used. For more than two sets 
of matched data, a two-way ANOVA with a Bonferroni (Papers I and IV), a Dunnett’s (Paper 
II) or a Tukey (Paper V) post-test was conducted. 
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RESULTS AND COMMENTS 
 
EPITHELIAL RECEPTOR PATTERN IN UPPER AIRWAY INFLAMMATION 
(PAPERS I-III) 
Traditionally, the role of ECs in innate immunity has been limited to features like barrier 
function, mucous production and cilia activity. Today, the role of ECs is believed to be much 
more complex with a close interaction with the adaptive part of the immune system. 
Expression of MHC class II and co-stimulatory molecules 
Expression of MHC class II molecules on the cell surface is crucial for antigen presentation to 
lymphocytes. Hence, we mapped the expression of MHC class II on isolated NECs, as well as 
co-stimulatory molecules (cluster of differentiation (CD) 86 and CD80) necessary for full  
T cell activation. We found a marked expression of H2-IAb (a mouse allele of MHC class II), 
CD86 and CD80 on naïve MNECs (Fig. 11A). We sensitized mice with OVA to mimic allergic 
patients. NECs from OVA-sensitized mice expressed increased levels of H2-IAb and CD80 
(Fig. 11B-C).   
Human samples were obtained before the start of the pollen season from healthy controls  
(Fig. 12A) and from patients with birch pollen-induced AR (Fig. 12B), confirming cell-surface 
expression of HLA-DR (one of the human MHC class II molecules) and CD86.  
 
 
Figure 11. Expression of H2-IAb, CD86 and CD80 on freshly isolated MNECs from (A) a naïve mouse and  
(B) from an OVA-sensitized mouse. (C) Expression of MHC class II, CD86 and CD80 on cultured MNECs from 
naïve and OVA-sensitized mice (n = 3-4).  
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Figure 12. Expression of HLA-DR and CD86 (open histogram) in cultured HNECs from (A) a healthy control 
and (B) an AR patient. Filled histogram represents isotype control.   
 
Mucosal TLR expression 
We continued studying TLRs, known to initiate an immune response upon binding conserved 
microbial components. A scarce amount of TLR9 expressing NECs were detected in the 
turbinate tissue of CRSwNP patients. In contrast, healthy controls had relatively high amounts 
of TLR9 expressing NECs in turbinate tissue (Fig. 13). Polyp tissue demonstrated an increased 
percentage of NECs expressing TLR9 compared to surrounding turbinate tissue from 
corresponding patients. This did however not reach statistical significance.  
 
Figure 13. Expression of TLR9 on turbinate epithelial cells from healthy controls compared to turbinate and polyp 
epithelial cells from CRSwNP patients, n = 5. 
 
ALK expression in nasal mucosa 
Recent investigations into causes of airway inflammation have revealed a role for the TGF-β 
superfamily upon binding to ALKs. We continued mapping the expression of ALKs on NECs 
from CRSwNP patients. IF revealed a strong presence of ALKs in the epithelial layer of the 
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polyps but merely a low to moderate expression in turbinate tissue from healthy controls  
(Fig. 14A-D). ALK expression on NECs was further quantified with flow cytometry revealing 
an increase of ALK1-6 on polyp ECs (Fig. 15). Upon further mapping of local proliferation 
and inflammation, IHC and flow cytometry revealed an increased expression of Ki67 and 
ICAM-1 and an increased release of IL-8 from polyp ECs compared to control cells  
(Fig. 16A-F). 
 
 
Figure 14. ALK expression in human nasal biopsies from CRSwNP patients and healthy controls (n = 3-4). ALK 
(green), EpCAM (red), co-localized expression of ALK and EpCAM (yellow), nucleus DAPI (blue) and ALK 
localized in the nucleus (light-blue). (A) ALK2, (B) ALK3, (C) ALK5 and (D) ALK7. Scale bar: 50 µm. 
 
COMMENTS 
The present studies revealed that NECs have the receptor pattern necessary for antigen 
presentation and that sensitized mice have upregulated receptor levels. In addition, NECs from 
CRSwNP patients express less TLR9 on turbinate ECs and more ALK1-6 as well as Ki67, 
ICAM-1 and IL-8 on polyp ECs compared to healthy controls. 
The ability to recognize and react against foreign antigens and activate lymphocytes has been 
assigned to traditional APCs like DCs, macrophages and certain B cells. At the same time, it 
has become generally accepted that ECs are far more complex in function than previously 
thought and that they as well can express MHC class II molecules. MHC class II molecules 
have previously been reported on cells from multiple tissues during inflammatory  
conditions.35-38, 40 We could detect MHC class II and co-stimulatory molecules on NECs from 
AR patients as well as from mice, thus confirming previous data of the field.39 The expression 
of MHC class II molecules and CD86 was upregulated in OVA-sensitized mice, bringing new 
descriptive knowledge to the subject.  
Intestinal ECs (IECs) are just like airway ECs positioned in the interface between the immune 
system and an environment scattered with antigens. In humans, CD86 was not detected on 
normal human IECs66 but upregulated on IECs from patients with inflammatory bowel 
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disease.67 Likewise, HLA-DR and CD86 was found to be increased on ECs from patients with 
eosinophilic esophagitis35 and on NECs from AR patients in season compared to pre pollen 
season. However, no comparative data from healthy controls were included in the study.35 We 
detected an increased amount of MHC class II molecules and CD80 on MNECs from sensitized 
mice but no upregulation in AR patients likely because samples were taken outside pollen 
season. 
We have previously demonstrated the expression of TLR9 in nasal mucosa54 and a reduced 
expression of TLR9 on ECs from nasal mucosa of rhinitis patients (persistent AR and CRS) 
has been reported.68 This downregulation seem transient, since AR patients outside pollen 
season displayed TLR9 on NECs similar to healthy controls.25 A decreased TLR9 expression 
on mRNA level has been found in paranasal sinus mucosa from patients with recurrent 
CRSwNP, compared to patients experiencing milder disease.52 We here reveal that the nasal 
mucosa adjacent to the polyps express almost no TLR9.  TLR9 is known to induce Th1 related 
activities known to suppress Th2-biased immune responses associated with CRSwNP.  
 
 
Figure 15. ALK expression on epithelial cells from CRSwNP patients (n = 13) and healthy controls (n = 8) 
examined with flow cytometry. 
 
Six out of seven ALKs were upregulated on polyp NECs. ALKs are receptors thought to be 
mainly anti-inflammatory upon ligand stimulation.58, 69 Limited research has to date been done 
on the potential distribution of ALKs in humans, and even less in the upper airways. 
Kariyawasam et al. detected ALKs on bronchial EC from asthma patients.70 Upon allergen 
challenge, expression of ALK1 and ALK4 increased while ALK5 expression decreased. 
Activin A was found to induce proliferation but not chemokine or cytokine release from 
bronchial ECs. This suggests a role for Activin A signaling through ALK4, in tissue repair and 
resolution of inflammation in asthma after allergen challenge.  
To summarize, this first part of the thesis describes the presence of MHC class II and co-
stimulatory molecules on NECs and an upregulated mucosal expression of TLR9 and  
ALK1-6 in CRSwNP patients. This suggests that the local epithelium can present antigens, 
initiating an adaptive immune response. Further, the presented data proposes a role for TLR9 
and ALK1-6 in CRSwNP. 
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Figure 16. Nasal biopsies from CRSwNP patients and healthy controls. Staining with IHC and quantification with 
flow cytometry (n = 5-8). (A) Ki67 staining and (B) quantification on ECs. (C) IL-8 staining and (D) quantified 
release from cultured ECs. (E) ICAM-1 staining and (F) quantification on ECs.  
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FUNCTIONAL ROLES OF NASAL EPITHELIAL RECEPTORS (PAPERS I-III) 
In order to further substantiate the role of epithelial receptors, functional experiments were set 
up using relevant antigens and ligands. 
Epithelial cells affect Th2 inflammation  
Co-culture experiments were designed to study if NECs could interact with T cells. We chose 
a well-established transgenic mouse system - OT-II mice carrying a transgenic TCR specific 
for a H2-IAb presented OVA peptide amino acid 323-339 - as well as OVA-sensitized mice 
and naïve mice. 
 
 
Figure 17. OVA-stimulated MNECs co-cultured with T cells. (A) MHC class II expression on MNECs (4 hours). 
(B) CD4+ T cell counts (24 hours). 
 
MNECs were co-cultured with increasing amounts of ovalbumin in the presence of T cells. 
NECs from sensitized mice exhibited an enhanced expression of MHC class II upon co-culture 
with OT-II T cells compared to naïve T cells (Fig. 17A). The number of OT-II CD4+ T cells in 
the same co-cultures was increased and a similar trend was also seen when OVA-sensitized  
T cells were used as reporter cells (Fig. 17B).  
The T cells in the co-cultures were further studied. Activated T cells display activation markers 
such as CD69 and CD44. CD69 represent the earliest T cell activation marker and is not 
displayed on resting lymphocytes.71 CD44 is a late activation marker, mediating adhesion to 
endothelium upon ligand binding.72 When NECs from sensitized mice were used as APCs, 
there was a pronounced increase of activated CD69 expressing OT-II T cells (Fig. 18A-B). The 
same findings were observed when using T cells from OVA-sensitized mice as reporter cells 
(Fig. 18A-B). In addition, MNECs from sensitized mice augmented the amount CD44+ OT-II 
cells, as well as sensitized T cells, seen in a dose-dependent manner (Fig. 18C-D). Sensitized 
MNECs did not affect the fraction of CD69+ T cells in co-cultures with neutralizing anti-MHC 
class II antibodies (Fig. 18E). IFN-γ release was measured in the supernatants as a marker of 
functional T cell activation. Sensitized OVA-stimulated MNECs were able to induce naïve  
OT-II T cells to release IFN-γ although statistical significance was not reached (Fig. 18F) and 
a similar tendency was seen from co-cultures with sensitized CD4+ T cells.  
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Figure 18. T cells and IFN-γ release upon co-culture with OVA-stimulated MNECs (24 hours). Color box legends 
valid for A-D and F. (A) Fraction and (B) total number of CD69+/CD4+ T cells. (C) Fraction and (D) total number 
of CD44+/CD4+ T cells. (E) Co-cultures with MNECs and T cells (both from sensitized mice) with anti–MHC 
class II antibodies (anti-MHC II). (F) INF-γ release in supernatants of co-cultures. 
 
CPG stimulation influences inflammation and angiogenesis 
To investigate whether the ligand CpG could affect or even restore the TLR9 expression, NECs 
were cultured and stimulated with CpG. ECs of turbinate tissue from CRSwNP patients 
upregulated the TLR9 expression upon CpG stimulation (Fig. 19A). CpG stimulation also 
decreased the levels of VEGFR2 (Fig. 19B), a receptor of angiogenesis, as well as decreased 
the levels of secreted G-CSF, IL-6 and MIP-1β (Fig. 20A-C). No differences were seen 
regarding TLR9, VEGFR2 or cytokines when cultured NECs from patient polyps or healthy 
controls were stimulated with CpG. 
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Figure 19. Cultured NECs from patients and healthy controls stimulated with CpG. (A) TLR9 expression upon  
4 hours and (B) VEGFR2 expression upon 24 hours of stimulation. n = 6, *p < 0.05; **p < 0.01 (un-stimulated vs. 
CpG stimulated) and ##p < 0.01 (un-stimulated turbinate tissue from patients vs. un-stimulated turbinate tissue 
from healthy controls and polyp tissue from patients). 
 
Activation of ALKs affect local proliferation and inflammation 
Cultured NECs were stimulated with multiple ALK ligands whereupon markers of 
proliferation (Ki67) and inflammation (ICAM-1 and IL-8) were measured. Upon stimulating 
ALK1 and 5 with TGF-β1, a downregulation of Ki67 expression (Fig. 21A) and IL-8 release 
(Fig. 21B) was detected from polyp ECs. In addition, stimulation of ALK2, 4 and 7 with 
Activin A or ALK4 and 7 with Activin B decreased ICAM-1 expression and IL-8 release from 
polyp ECs (Fig. 21C-F). Control ECs showed no change in Ki67 or ICAM-1 expression or  
IL-8 release upon ALK stimulation (Fig. 21A-F). 
COMMENTS 
An efficient T cell response is crucial in an inflammatory response. Upon stimulating co-
cultures of MNECs and T cells in an antigen-specific manner (OVA), MNECs upregulated 
their MHC class II expression. No upregulation was seen when MNECs were co-cultured with 
naïve splenic cells. This demonstrates the essence of antigen presentation and interaction of 
0 0 .1 0 .3 1 .0 0 0 .1  0 .3 1 .0 0 0 .1 0 .3 1 .0
0
2 0
4 0
6 0
8 0
1 0 0
C p G  (M )
* *
* *
* *
# #
T u rb in a te  tis s u e , h e a lth y
T u rb in a te  tis s u e , C R S w N P
P o ly p  tis s u e , C R S w N P
# #
T
L
R
9
+
 e
p
it
h
e
li
a
l 
c
e
ll
s
 (
%
)
A
B
0 0 .1 0 .3 1 .0 0 0 .1 0 .3 1 .0 0 0 .1 0 .3 1 .0
0
2 0
4 0
6 0
8 0
1 0 0
C p G  (M )
* *
# #
# #
*
* *
V
E
G
F
R
+
 e
p
it
h
e
li
a
l 
c
e
ll
s
 (
%
)
  31 
antigen-specific T cells. Thus, sensitized MNECs upregulate their antigen presenting capacity 
upon OVA-stimulation in a TCR-specific manner. In addition, the total number CD4+ T cells 
and their level of activation, demonstrated by the expression of CD69 and CD44, was increased 
upon stimulation in the same co-cultures. The OVA peptide used encompasses an allergic 
antigenic epitope of the OVA protein in mice. Hence, activation of OT-II T cells by OVA 
requires antigen processing. This event is class II dependent, revealed by the assays with MHC 
class II-blocking antibodies. Altogether, we claim that sensitized MNECs can take up, process 
and present antigens and cause an antigen specific CD4+ T cell response in a class II dependent 
manner.  
Kambayashi et al. published a review on the subject ‘atypical APCs’, questioning what role 
they could have in immune responses.73 They concluded that a large number of cells can 
express MHC class II molecules and present antigens to CD4+ T cells. MHC class II molecules 
alone are however not sufficient for full APC function, since APCs also need to process 
antigens and express co-stimulatory molecules for lymphocyte activation. They argue that non-
professional APCs are unlikely to replace DCs, since there has hardly been shown that these 
cell types are able to activate naïve CD4+ T cells. We do not claim that NECs can replace the 
role of professional APCs. However, the use of a TCR transgenic system (OT-II mice) and 
murine ECs made it possible for us to use naïve T cells as reporter cells, thus proving that a  
T cell response against allergens could be initiated by ECs.  
 
 
Figure 20. Cytokine secretion from cultured NECs upon 4 or 24 hours of CpG stimulation. (A) G-CSF, (B) IL-6 
and (C) MIP-1β. *p < 0.05; **p < 0.01 (un-stimulated vs. CpG stimulated), # p < 0.05 (un-stimulated turbinate 
tissue from healthy controls vs. from patients). 
 
We continued studying human NECs from CRSwNP patients in vitro. Several studies have 
reported on immunostimulatory properties of CpG in vitro in humans74, 75 and in vivo in  
mice.76, 77 These findings reveal the ability of CpG to promote a Th1-biased immune 
response.56, 75 We here showed that the pronounced decrease in TLR9 expression on patient 
NECs (Fig. 13) could be restored towards healthy conditions upon CPG stimulation. In 
addition, CpG stimulation decreased the expression of VEGFR2, a receptor necessary for 
vascular supply thus facilitating the growth of nasal polyps78, 79 and often upregulated in 
CRSwNP.80, 81 Hence, CpG seem to regulate inflammation and angiogenesis in CRSwNP. 
We have previously shown that factors affecting local proliferation (Ki67) and inflammation 
(ICAM-1 and IL-8) were increased in CRSwNP (Fig. 16A-F). Stimulation with ALK ligands 
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downregulated all these factors. Since the levels of the two ALK ligands TGF-β1 and Activin 
A have been shown to be low in CRSwNP, absence of ALK-activation might contribute to 
inflammation in this disease.69, 82, 83 
Altogether, these results demonstrate that NECs can activate and proliferate CD4+ T cells in an 
antigen specific manner. Activation of TLR9 and ALKs resulted in cytokine release and 
changes in the receptor pattern, linked to inflammation, angiogenesis and cell-proliferation. 
The presented data suggests a role for these receptors in the local nasal inflammation, 
something that is further underscored by the changes in the receptor patterns seen during 
inflammatory conditions. 
 
 
Figure 21. Cultured NECs stimulated with ALK ligands for 24 hours. (A-B) TGF-β1, (C-D) Activin A and (E-F) 
Activin B. Expression of Ki67 and ICAM-1 as well as secreted IL-8 was measured. Specimen from turbinate tissue 
from healthy controls and polyp tissue from CRSwNP patients. 
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NEUTROPHIL SUBSETS IN THE NOSE (PAPERS IV, V) 
Neutrophils have long been considered as short-lived, terminally differentiated cells. However, 
information has recently emerged indicating that neutrophils can be divided into different 
functional subsets, based on the expression of CD16 and CD62L.  
 
 
Figure 22. Fractions of neutrophils in (A) blood, (B) nasal biopsies and (C) NAL from patients with AR during 
pollen season and healthy controls. 
 
The distribution of neutrophil subsets in AR 
We started with determining the total neutrophil fractions in AR. Neutrophil fractions were 
found to be enhanced in blood, nasal biopsies and NAL from AR patients during pollen season, 
compared to healthy controls (Fig. 22A-C). We classified the neutrophils into four different 
subsets (Fig. 23A). The less mature subset, CD16dim CD62Lhigh, was hardly detectable. The 
mature subset, CD16high CD62Lhigh, was mainly found in blood. In nasal mucosa, both the 
CD16high CD62Lhigh subset and the activated form, CD16high CD62Ldim, were elevated. Finally, 
the subsets CD16high CD62Ldim and CD16dim CD62Ldim, considered the end state neutrophil, 
were elevated in NAL. Healthy controls exhibited the same general compartmental subset 
pattern as the AR patients with more differentiated subsets in nasal mucosa and even more in 
NAL compared to in peripheral blood (data not shown). The activated neutrophil subset, 
CD16high CD62Ldim, was elevated compared to the mature neutrophil subset  
CD16high CD62Lhigh in biopsies from AR patients (Fig. 23B). This was not seen in healthy 
controls. 
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Figure 23. Fractions of different neutrophil subsets. (A) Neutrophil subsets in blood, nasal biopsies and NAL from 
AR patients during pollen season. (B) Distribution of neutrophil subsets in nasal biopsies from AR patients and 
healthy controls during pollen season.  
 
The distribution of neutrophil subsets in CRSwNP 
We continued mapping neutrophils in CRSwNP. We saw no differences in the total neutrophil 
fractions in blood or tissue between patients and controls (Fig. 24A-B). When subtyping the 
neutrophils as in AR patients, we detected a clear shift. The activated neutrophil subset, 
CD16high CD62Ldim, was higher in patient polyp mucosa compared to control mucosa  
(Fig. 25A). A similar trend, not reaching statistical significance, was also seen for  
CD16high CD62Ldim neutrophils found in the surrounding nasal mucosa of patients (p = 0.3). 
Moreover, the end state subset, CD16dim CD62Ldim, was also increased in patient polyp mucosa 
compared to healthy controls. On the other hand, the mature neutrophil subset,  
CD16high CD62Lhigh, dominated in control mucosa (Fig. 25A). Polyps exhibited a significantly 
higher ratio of activated neutrophils compared to normal neutrophils (Fig. 25B) or end state 
neutrophils compared to normal neutrophils (Fig. 25C), highlighting the shift towards more 
activated and differentiated neutrophils in the nasal mucosa from patients. 
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COMMENTS 
Neutrophil subsets are present in the nasal mucosa and activated and differentiated subsets are 
increased locally in allergy and CRSwNP. The shift towards more activated neutrophils in the 
mucosa of patients was more pronounced in CRSwNP whereas the increase in total number of 
neutrophils was more marked in AR, indicating a substantial increase of the activated subsets 
also in AR. 
Eosinophils are known to play a part in both allergy and CRSwNP. Even though the neutrophils 
far outnumber the number of eosinophils found both locally and systemically during these 
conditions, the former has been given much less attention as a potential player in the 
inflammatory reaction. This is probably due to the fact that neutrophils always can be found in 
the nose, also in the asymptomatic allergic phase, and in healthy controls. The finding of 
different subsets with different immunological properties has however changed the concept of 
neutrophil studies.45 Sauce et al. reported that elderly patients have increased levels of activated 
CD16high CD62Ldim neutrophils in the blood compared to healthy controls.84 The same subset 
has been proven to be increased in blood in patients with various cancer diagnoses.85 
 
 
 
Figure 24. Fractions of neutrophils in (A) blood and (B) in patient surrounding nasal mucosa and polyps as well 
as in nasal mucosa from healthy controls. 
 
Neutrophils from allergic patients have at the same time been shown to downregulate the 
surface expression of CD62L upon allergen stimulation.86 In line with this, we have previously 
demonstrated that neutrophils in NAL from allergic patients have a downregulated expression 
of L-selectin (CD62L) during the peak of the pollen season.87 The distribution of neutrophil 
subsets based on their expression of CD16 and CD62L has never been studied in AR. Neither 
have they been mapped in CRSwNP. In addition, little attention has previously been paid to 
the end state subset, CD16dim CD62Ldim neutrophils. We believe it to still have functional 
properties as with the CD16high CD62Ldim subset, because of the viability experiments. We here 
report that activated and differentiated neutrophil subsets accumulate locally at the site of 
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disease, making it tempting to suggest a role for these subsets in nasal allergy as well as 
CRSwNP. 
 
 
 
Figure 25. (A) The distribution of neutrophil subsets in patient surrounding nasal mucosa and polyps as well as 
nasal mucosa from healthy controls. Ratio of (B) activated neutrophils compared to normal neutrophils and  
(C) end state neutrophils compared to normal neutrophils. 
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INNATE MECHANISMS OF THE EPITHELIUM AND NEUTROPHILS AFFECT 
ALLERGIC INFLAMMATION (PAPERS I, IV) 
Nasal inflammation, where the innate immune system immediately reacts to invading 
pathogens, is a major feature of AR. The epithelium and neutrophils play a role in this, but the 
mechanisms behind this is rather unknown. 
Epithelial cells induce autologous CD4+ T cell allergen responses 
We wished to further validate the idea of HNECs as APCs, suggested by expression of MHC 
class II and co-stimulatory molecules (Fig. 12A-B), and to investigate whether this action could 
be upregulated in allergy. Accordingly, the ability of HNECs to endocytose exogenous antigens 
was investigated by providing FITC labeled dextran to cultured HNECs derived from an AR 
patient. IF demonstrated the presence of dextran in intracellular vesicles after 2 hours 
suggesting that NECs could endocytose exogenous antigens (Fig. 26A-B).  
We continued allowing cultured HNECs to endocytose a crude birch pollen extract. 
Autologous T cells harvested in-season during periods of high pollen counts were subsequently 
added to the co-cultures. We observed an increase in the number of autologous CD4+ T cells 
when co-cultured with stimulated HNECs from AR patients (Fig. 26C). In the following 
experiments, we used the major birch allergen protein, Bet v 1, minimizing endotoxin 
contamination. Autologous CD69+/CD4+ T cells increased upon co-culture with stimulated 
HNECs from AR patients (Fig. 27A). IL-13 release was augmented in the same co-cultures 
(Fig. 27B). We finally analyzed the distribution of different HLA-DR expressing cells in the 
nasal mucosa, revealing a high number of HLA-DR expressing ECs, compared to HLA-DR 
expressing professional APCs (Fig. 27C). The expression of HLA-DR was rather high in 
NECs, demonstrated by the MFI (Fig. 27D).  
 
 
Figure 26. (A) Endocytotic uptake of exogenous antigens (dextran, in green) by NECs from a patient with AR, 
co-localizing with MHC class II molecules (red) intracellularly in vesicles. Nucleus counterstained with DAPI 
(blue). (B) A three-dimensional composite image showing co-localization. Scale bar: 10 µm. (C) Levels of CD4+ 
T cells after co-culture with HNECs stimulated with birch pollen.  
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Figure 27. Human NECs. (A) The fraction of CD69+/CD4+ T cells and (B) the IL-13 release followed co-culture 
with HNECs stimulated with Bet v 1. (C) Different HLA-DR+ cell types in nasal mucosa and (D) the MFI. 
 
Activated neutrophils can prime T cells and mediate eosinophil migration 
Neutrophils were isolated from blood and stimulated with LPS, TNF-α and IL-8 to cause 
activation. Flow cytometric analysis revealed an increase of the activated neutrophil subset 
(CD16high CD62Ldim) (Fig. 28). Autologous T cells from blood were added in co-cultures.  
T cells primed with activated neutrophils were more likely to get activated by CD3 stimulation, 
demonstrated by the CD69 expression (Fig. 29A). The same findings were observed when 
using blood from AR patients (Fig. 29B).  
 
Figure 28. Flow cytometric dot plot of neutrophils from blood before and after activation with LPS, TNF-α and 
IL-8.  
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Experiments carried out on transwell plates did not reveal an increase of CD69+/CD4+ T cells 
upon priming with activated neutrophils (Fig. 29C), indicating that the enhanced T cell priming 
of neutrophils was cell-cell contact or close contact dependent. Assays were finally set up to 
study the impact of activated neutrophils on eosinophils. Isolated neutrophils stimulated with 
LPS, TNF-α and IL-8 upregulated eosinophilic migration in the transwell system (Fig. 30). 
 
 
Figure 29. T cells primed by activated neutrophils. The fraction of CD69+/CD4+ T cells from (A) healthy 
individuals (n = 12) and (B) AR patients (n = 5) primed with naïve or activated neutrophils. (C) Experiments with 
and without transwell plates (n = 11). Control = no added neutrophils. 
 
COMMENTS 
NECs from AR patients exhibited an increased capacity to activate autologous CD4+ T cells in 
an allergen-specific manner, further corroborating the mouse data presented (Fig. 17-18). This 
recall response was likely to result in a Th2-biased response reflected by the secretion of  
IL-13. In addition, HLA-DR+ HNECs far outnumbered local HLA-DR+ DCs, B cells and 
macrophages. Thus, the ability of NECs to act as APCs is an important event in the first line of 
defense in the nasal mucosa, being constantly exposed to allergens. In addition, professional 
APCs are fewer in total numbers88, 89 and believed to mainly present and subsequently activate 
T cells in the lymph nodes, not locally in the nose.  
The idea of more advanced immunological properties of ECs is gaining acceptance. It enables 
a rapid and potentially efficient nasal immunological defense considering ECs strategic 
localization, vast numbers and rapid innate action. Experiments in Paper I was both conducted 
with mouse and human cells. The different set ups make up for each other since they have 
different advantages. The mice model allowed the usage of transgenic systems as well as naïve 
T cells, making it possible to draw more reliable conclusions on the capacities of NECs. Adding 
human experiments, on the other hand, enabled conclusions on a clinical level. True allergic 
patients were included, unlike the allergic model used in mice. 
How antigen presentation by ECs can contribute to a disease has to date scarcely been 
investigated. Dotan et al. revealed that IECs from patients with inflammatory bowel disease 
stimulated CD4+ T cells more efficiently than control IECs.36 Deleting MHC class II expression 
exclusively on podocytes, terminally differentiated visceral ECs in kidneys, prevented the 
induction of anti-GBM nephritis in mice.37 An upregulated expression of MHC class II 
molecules on mice type II alveolar ECs has been reported following infection with 
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Mycobacterium tuberculosis, suggesting that a rapid response with local antigen presenting 
ECs is important for the initiation of an early adaptive immune response.90 Several viruses, for 
example causing severe acute respiratory syndrome (SARS), have developed mechanisms to 
inhibit MHC class II pathways in ECs, indicating them as important in the defense against 
viruses.91 Upregulated levels of HLA-DR and CD86 have been reported on primary NECs from 
AR patients during the pollen season.39 Bet v 1 has further been demonstrated to bind to and to 
enter ECs rapidly (within minutes) after the exposure even in allergic patients during the non-
symptomatic season.92 Despite these findings, the function of airway ECs as significant 
contributors to the allergic reaction remains to be established.  
 
 
Figure 30. Eosinophil migration upon incubation with naïve or activated neutrophils in transwell systems  
(n = 4-5). Control = no added neutrophils. 
 
Neutrophils are, just like ECs, an abundant cell type in the nasal mucosa. Different subsets have 
been suggested to have diverse roles during various inflammatory conditions. The subset 
CD16high CD62Ldim was shown to have a lower phagocytic index as well as a lower oxidative 
burst compared to the normal mature neutrophil subset.84 This was suggested to partly explain 
the susceptibility to microbial infections during aging. On the other hand, we have previously 
shown activated neutrophils to have protective aspects in head and neck squamous cell 
carcinoma.93, 94 We here showed that activated neutrophils could prime T cells, thus facilitating 
T cell activation. In contrast to this, Pillay et al. reported that activated neutrophils suppressed 
T cell activation. These experiments were however in model systems using blood from healthy 
volunteers while our experiments used cells from allergic patients (Fig. 29B). Eosinophils are 
known to play an important role in Th2-mediated allergic immune responses.95, 96 The 
presented data revealed that activated neutrophils could facilitate eosinophil migration. This 
assigns neutrophils a novel role in allergy. Interestingly, reduced numbers of neutrophils have 
been recorded following immunotherapy.97, 98 Thus, we concluded that activated neutrophils 
are likely to enhance eosinophil migration in allergy, facilitating the local eosinophil infiltration 
seen in this condition.  
To sum up, this is the first time that innate activity within the nasal epithelium has been directly 
linked to efficient and rapid allergen-induced T cell activation. Activated neutrophils in the 
mucosa were shown to augment this process. These neutrophils could also enhance eosinophil 
migration. Allergen exposure is known to result in a high number of activated CD4+ T cells 
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and eosinophils in the nasal mucosa and an increase of cells expressing Th2 cytokines.99 Hence, 
the local epithelium and neutrophils are likely to rapidly contribute to this well-known allergic 
inflammatory process upon allergen exposure.  
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TARGETING INFLAMMATION IN CRS THROUGH INNATE MECHANISMS 
(PAPERS II, III, V) 
The theories about the mechanisms involved in CRSwNP progression are becoming 
increasingly complex, without identifying the pivotal factors behind the growth of polyps.19  
A re-examination of old concepts may thus be necessary to find novel treatment strategies. 
CpG challenge in vivo has potential anti-inflammatory effects 
Patients requiring surgical intervention for CRSwNP were intra-nasally challenged with CpG 
or placebo. After 24 hours, biopsies from mucosa surrounding the polyps were taken during 
FESS. Flow cytometry revealed an upregulation of TLR9+ NECs as well as a tendency towards 
a downregulation of VEGFR2+ NECs in the CpG challenged group (Fig. 31A-B). These data 
confirmed the in vitro data presented (Fig. 19), indicating that CpG augments the TLR9 
expression and decreases the VEGFR2 expression. In addition, these data are in line with the 
in vitro data of the epithelium in the mucosa surrounding the polyps and highlights the 
immunological potential of this mucosa.  
 
 
Figure 31. Expression of (A) TLR9 and (B) VEGFR2 on epithelium surrounding the polyp, 24 hours after in vivo 
nasal challenge with CpG or placebo. 
 
ALK activation reduces mimicked microbial inflammation in CRSwNP 
We earlier demonstrated that ALK-stimulation reduced ICAM-1 expression on NECs from 
CRSwNP patients (Fig. 21C, E). Infections are known to trigger periods of disease progression. 
Hence, cultured NECs pre-treated with the ALK-ligands TGF-β1, Activin A, BMP4 and 
Activin B were subsequently exposed to TNF-α, a cytokine known to be produced upon 
bacterial, fungal and viral infections. Pre-treatment with ALK-ligands significantly inhibited 
TNF-α induced ICAM-1 expression on polyp ECs (Fig. 32). 
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Figure 32. Cultured NECs stimulated with (A) TGF-β1, (B) Activin A, (C) BMP4 and (D) Activin B for 20 hours 
whereupon TNF-α was added and incubated for 4 hours and ICAM-1 expression was determined. Specimen from 
polyp tissue from CRSwNP patients and turbinate tissue from healthy controls (n = 5-7).  
 
Neutrophils from patients have greater possibilities for mucosal adhesion 
To further explore the impact of activated neutrophils locally in patients with CRSwNP, we 
studied the protein subunit CD11b. Together with CD18, it forms a heterodimeric integrin 
mediating inflammation by regulating leucocyte adhesion and migration, implicating cell 
activation. This occurs by binding to the cell surface molecule ICAM-1. Neutrophils both in 
blood (Fig. 33A) and nasal mucosa (Fig. 33B) from CRSwNP patients exhibited higher 
fractions of CD11b+ cells compared to healthy controls. The nasal mucosa surrounding the 
polyps showed the same pattern regarding CD11b. The expression of CD11b was most 
prominent on CD16high CD62Lhigh and CD16high CD62Ldim neutrophils in patient blood  
(Fig. 34B). Activated CD16high CD62Ldim neutrophils exhibited the highest expression of 
CD11b both in patient mucosa and polyps (Fig. 34D, E). No such shift was seen in healthy 
blood or mucosa (Fig. 34 A, C). Correspondingly, ICAM-1 was significantly upregulated on 
ECs from polyps (Fig. 35).  
COMMENTS 
Inflammatory exacerbations combined with polyp growth are regularly seen in conjunction 
with upper airway infections in CRSwNP.14 Several bacteria have been isolated from the 
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sinuses in CRS100, although much focus have been placed on Staphylococcus aureus and its 
enterotoxin products (SAE).101-103 The relationship between Staphylococcus aureus and 
CRSwNP is still not fully established, even though there is a consensus about the role for a 
locally disturbed microbial flora in the disorder.104, 105 It might be that the polyp growth is not 
directly linked to the invading pathogen, but rather to the trauma that the pathogen causes.106 
Presented ligand stimulation of epithelial ALKs decreased ICAM-1 more prominently in the 
presence of TNF-α, signaling a tentative anti-inflammatory effect of these receptors. 
 
 
Figure 33. The expression of the surface marker CD11b on neutrophils from (A) blood and (B) patient surrounding 
nasal mucosa and polyps as well as nasal mucosa from healthy controls. 
 
CpG is a TLR9 ligand found in viral and bacterial DNA. The ability of CpG to induce  
Th1 polarization has been suggested to have a potential protective role against  
Th2 inflammation.  A recent study showed no effects on IL-5 or eotaxin-3 upon CpG 
stimulation.107 On the other hand, matrix metalloprotease 9 (MMP-9) - an important protein in 
tissue remodeling and repair - was elevated in stimulated cell cultures from CRS patients. 
However, the study suffers from some weaknesses. Patients with inverted papilloma were used 
as controls and patient samples incubated with negative controls also appeared to have 
increased MMP-9.107 Hence, we still believe that CpG could have a protective role in CRSwNP 
patients by lowering inflammation and preventing an angiogenetic milieu of the epithelium. 
Kamp et al.46 reported that the neutrophil subset CD16high CD62Ldim had a decreased ability to 
adhere to endothelium in vitro, possibly resulting in less extravasation of activated neutrophils 
from the blood. The subset was instead suggested to preferentially migrate to peripheral 
lymphoid organs. The authors reported on upregulated CD11b on activated neutrophils and 
questioned what consequences this finding could have in vivo. We saw no increase in activated 
neutrophils in blood from patients with CRSwNP, but they were increased in the nasal mucosa. 
We suggest that the neutrophils are activated in the sinonasal mucosa, probably due to local 
IL-8 and IL-17. We propose these CD16high CD62Ldim neutrophils to have enhanced adhesion 
to the epithelium in the nasal mucosa by CD11b and ICAM-1 interactions, since these receptors 
were upregulated on the neutrophils and epithelial cells of patients. Future studies will 
hopefully answer what role the activated subsets can play in CRSwNP and whether targeting 
them or CD11b/ICAM-1 can facilitate disease control. 
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Figure 34. Expression of CD11b on different neutrophil subsets from (A) healthy blood, (B) patient blood,  
(C) nasal mucosa from healthy controls, (D) nasal mucosa from CRSwNP patients and (E) polyps from CRSwNP 
patients (n = 11-16). 
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The nasal mucosa with its epithelial receptors appears to change during inflammatory 
conditions and targeting these receptors must therefore be considered in future therapeutic 
efforts. The surrounding nasal mucosa seen not far from the polyps seem to be of special 
interest for some of these mechanisms. Hence, researchers should consider analyzing not only 
the diseased tissue of the polyp but also the surrounding non-polypoid mucosa. 
 
 
Figure 35. ICAM-1 expression on epithelial cells from patient surrounding nasal mucosa and polyps as well as 
nasal mucosa from healthy controls. 
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CONCLUSIONS 
 
- Nasal epithelial cells express MHC class II and co-stimulatory molecules, necessary 
for antigen presentation, as well as TLR9 and ALKs. The presentation of these 
signaling molecules was found to differ between inflamed and healthy tissue. The 
presented data suggest that the local epithelium has the ability to present antigens and 
to influence the inflammatory process during upper airway disease. 
 
- Mouse nasal epithelial cells could activate and proliferate CD4+ T cells in an antigen 
specific manner. Stimulation of TLR9 and ALK1-6 resulted in cytokine release and 
changes in the receptor pattern, linked to inflammation, angiogenesis and cell-
proliferation. Hence, activation of these, during inflammatory conditions, modified 
receptors might have a direct or indirect impact on the ongoing inflammatory process.  
 
- Four neutrophils subsets could be characterized in the human nose and changes in the 
distribution of these subsets could be linked to the inflammatory process seen in AR 
and CRSwNP. Generally, the more activated and differentiated subsets were found to 
accumulate locally in patients, suggesting a role for them in upper airway disease.  
 
- The human nasal epithelium was shown to have the ability to amplify an allergic 
response thereby contributing to the ongoing CD4+ T cell-mediated inflammation. In 
addition, activated neutrophils in the nasal mucosa could prime T cells and enhance 
eosinophil migration. Since both T cells and eosinophils are central in the allergic 
response, the presented data underscore the role epithelial and neutrophil cells have in 
the fast response to allergens at the local site of exposure.  
 
- Ligand stimulation of TLR9 and ALK1-7, in vivo or in a model of microbial infection, 
were found to reduce local inflammation, angiogenesis and cell-proliferation. Further, 
an increased expression of CD11b on activated neutrophils and a corresponding 
upregulated expression of ICAM-1 on epithelial cells from CRSwNP patients was 
detected, suggesting a mechanism for a neutrophil-epithelial interaction in nasal polyps. 
These results indicate that targeting of local innate receptors can reduce inflammation 
and slow down disease progression in CRSwNP. 
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SUMMARY AND FUTURE PERSPECTIVES 
 
The traditional idea of the epithelium as a simple barrier and neutrophils as homogenous and 
terminally differentiated cells have lately been reconsidered. The present thesis details the role 
of ECs in antigen presentation and for the innate functions of TLRs and ALKs. In addition, it 
reports on a role for the activated neutrophil subset in nasal allergy and polyposis.  
ECs by far exceed the number of professional APCs in the nose. The same is true for HLA-
DR+ cells. The ECs are in place to meet the antigen when it enters the nose, whereas it normally 
takes several days to recruit professional APCs like DCs to the nose.108 Further, professional 
APCs activate T cells preferably in lymphnodes, not locally in the nasal mucosa. These facts 
emphasize the immunological value of the antigen presenting capacity of local ECs. 
New information indicates that neutrophils can be divided into different subsets, each with 
diverse roles during inflammatory conditions. The present thesis advances this concept further 
by describing the existence of neutrophil subsets in the nose, that a shift towards more activated 
subsets is seen in upper airway inflammation and that these subsets seem to have diverse 
functions in upper airway diseases.  
It was revealed that local epithelial and neutrophil cells in the nasal mucosa of patients with 
AR and CRSwNP, both characterized by a type 2-biased inflammation, exhibited an alerted 
receptor pattern with a deranged immunological response. Our data on T cell activation, cell 
migration and adhesion as well as cytokine release, clearly indicated a role for antigen 
presenting ECs, TLRs, ALKs and various neutrophil subsets in these upper airway 
inflammatory diseases.    
Human experiments (Paper I) disclosed a high percentage of HLA-DR+ ECs in the nose.  
It would therefore be of interest to compare the efficacy of these antigen presenting ECs to 
DCs, macrophages and B cells. An epithelial specific MHC class II knock out mouse would 
then be useful in order to further understand the role of aberrant class II expression and to 
explore whether MHC class II lacking selectively on ECs but normally expressed on immune 
cells would significantly affect the induction of inflammation. In a recent mouse model of 
inflammatory bowel disease, MHC class II deficient mice were fed Helicobacter hepaticus and 
IL-10 receptor-blocking antibodies. It was shown that transferred CD4+ T cells were unable to 
induce and reinstate tolerance, demonstrating the need for aberrant MHC class II expression.109 
Thus, it seems to be important for the initial protection against pathogens to have a local rapid 
response with an induced capability to present antigen and to activate CD4+ T helper cells. 
Steroids are commonly used to suppress local inflammation in CRSwNP and AR. These drugs 
are generally highly un-specific on a molecular level, making them effective in various 
inflammatory conditions but at the same time, rendering multiple side-effects.110 Oral steroids 
have more potent effects than topical steroids. Long-term usage is however not recommended 
due to the unwanted effects, resulting in recommendations on periodic treatment but with risk 
of disease recurrence.111 A key point in the development of new treatment strategies is to find 
targets to hit, minimizing these side-effects. Monoclonal antibodies, which dampen  
  49 
Th2 inflammation and IgE related activity, are presently tried out.18 These biologicals are 
however costly which limits their use in large patient cohorts.  
Stimulation of epithelial TLR and ALK receptors (Papers II and III) affected the inflammatory 
response as well as factors coupled to angiogenesis and cell proliferation in CRSwNP. It is 
tempting to speculate on a therapeutic role for the ligands of these receptors in the future 
treatment of CRSwNP and AR.  
Immunotherapy is an effective way to induce allergen tolerance. It requires three to five-years 
of treatment with daily medications or repeated injections. The tolerance inducing mechanisms 
are still not fully understood, but areas of interest include Th1/Th2, IL-10 and IgG4. Rather 
unnoticed is that this therapy also effects neutrophils.97, 98, 112, 113 Since data in the present thesis 
showed a role for the activated subset in allergy, it would be valuable to explore the effect of 
immunotherapy on the different subsets described in Paper IV. 
Activated neutrophils might increase airway inflammation through priming of T cells and 
increasing eosinophil migration. It would be of interest to explore whether blocking the 
activation procedure of neutrophils, likely taking place in the local mucosa, could have further 
anti-inflammatory effects. Leukapheresis is another desirable method, however requiring 
systemic detection of the cell type of interest.114 Perhaps CD11b+ neutrophils could be the target 
to explore in CRSwNP or AR.  
Paper V revealed a shift in neutrophil subsets in CRSwNP, favoring the more activated subset 
in the mucosa. An upregulation of CD11b and ICAM-1 on neutrophils and ECs respectively 
was also seen. Experiments evaluating the migrating capacity of CD16high CD62Ldim 
neutrophils might reveal the role for activated neutrophils in the inflammatory drive behind 
polyp development. Steroid treatment did not affect the findings on either neutrophil subsets 
nor CD11b or ICAM-1 expression. Thus, possible treatments interfering with neutrophils and 
the epithelium on this level could open up new perspectives for future management of 
CRSwNP, especially for the group of patients with weak or absent response to steroid 
treatment.  
The neutrophil subset CD16dim CD62Ldim has previously been described, although not further 
specified.45 Nor have experiments on potential immunological characteristics of this subset 
been published. We reported that this subset was increased in NAL of AR patients compared 
to nasal mucosa and blood, and that the same subset is increased in polyp mucosa from 
CRSwNP patients. Further experiments, purifying this subset for functional analysis, would 
answer which implications the presence of this subset could have. 
The results of this thesis increase the understanding of upper airway inflammation on a 
molecular level, hence encouraging future studies of more specific treatment strategies for 
CRSwNP and AR.  
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POPULÄRVETENSKAPLIG SVENSK SAMMANFATTNING 
 
Epitelceller i nässlemhinnan utgör en första barriär mot invaderande mikrober och antigener 
som virus, bakterier och pollen. På senare tid har man insett att detta ytskikt inte bara utgör en 
fysisk barriär, utan även besitter en immunologisk försvarsförmåga. Medfödda, så kallade 
innata, receptorer är av speciellt intresse i detta sammanhang. De har förmåga att känna igen 
och dra igång en immunologisk reaktion som svar på en invaderande mikrob. Denna 
avhandling har fokuserat på två receptorfamiljer av detta slag; toll-lika receptorer (TLRs) och 
activin receptor-lika kinaser (ALKs). Hur och i vilken utsträckning aktivering av dessa kan 
medverka i uppkomst av inflammatoriska tillstånd i näsan är ofullständigt känt. Avhandlingen 
har även utrett hur epitelceller kan agera som antigenpresenterande celler. 
Neutrofiler, den mest frekvent förekommande vita blodkroppen hos människor, finns alltid i 
blod och vävnad hos såväl friska som sjuka personer. En ökning i antal ses regelmässigt i 
samband med en infektion men ingen större betydelse har tillmätts neutrofilen i samband med 
utvecklingen av allergi och näspolypos. Kanske beror detta på att man betraktat neutrofiler som 
en tillsynes homogen, enhetlig cellpopulation. På senare tid har emellertid flera studier visat att 
så inte är fallet. Neutrofiler kan delas in i olika subpopulationer med hänsyn till vilka receptorer 
som vid en viss tidpunkt uttrycks på cellens yta. Variationer i uttrycket av ytreceptorerna 
FcγRIII (CD16) och L-selectin (CD62L) antas återspegla variationer i neutrofilens 
immunologiska egenskaper. 
Syftet med föreliggande avhandling är att kartlägga på vilket sätt TLR och ALK på epitelceller 
samt olika neutrofila subgrupper kan påverka uppkomst och utveckling av allergisk rinit och 
näspolypos. Avhandlingen utreder även hur epitelceller kan agera som antigenpresenterande 
celler. 
Delarbete I-III kartlägger uttrycket av ytreceptorer kopplade till antigenpresentation, TLRs 
samt ALKs på näsepitelceller. Epitel från såväl människa som mus har receptorer nödvändiga 
för antigenpresentation. Epitelceller från en allergisk musmodell (så kallade sensitiserade 
möss) samt från allergiska patienter kan både ta upp och bearbeta antigen och presentera 
slutprodukten för T celler, som därvid aktiveras. Detta sker inte med friska epitelceller från 
mus eller människa. Epitelceller verkar således spela en viktig för den allergispecifika 
inflammationen i näsan. Humana näsepitelceller i närheten av den plats i näsan där polyper 
vanligen bildas har ett mycket lågt uttryck av TLR9 i jämförelse med motsvarande 
nässlemhinna hos friska, polypfria individer. Om epitelcellerna stimuleras med ett för receptorn 
specifikt protein, CpG, återkommer dock det tidigare saknade TLR9-uttrycket. Aktivering av 
TLR9 hämmar även VEGFR2, en receptor kopplad till lokal kärltillväxt, liksom andra 
inflammationsdrivande signalsubstanser, så kallade cytokiner. Sålunda förefaller aktivering av 
TLR9 gynnsamt om man vill förhindra tillväxt av näspolyper. Uttrycket av ALK1-6 är 
uppreglerat på polypepitelceller från patienter. Om man stimulerade dessa receptorer med deras 
specifika ligander, vilka ofta är färre i antal hos näspolypospatienter, minskar de faktorer som 
gynnar celldelning (Ki67) samt inflammation (ICAM-1 och IL-8). ICAM-1 minskningen är 
speciellt påtaglig om man stimulerar med en tilläggsligand som imiterade effekten av en 
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attackerande mikrob. Då infektioner är en vanlig orsak till polyptillväxt talar detta för ALK-
inblandning i polypsjukdomen.  
I delarbete IV och V beskrivs för första gången förekomsten av olika neutrofila subgrupper i 
näsans slemhinna. En av populationen kan betraktas som aktiverad och deras antal ökar 
påtagligt hos patienter med allergi och näspolypos. Vi kunde visa att aktiverade neutrofiler i 
sin tur kan aktivera T celler samt underlätta migration av eosinofiler, två viktiga 
immunologiska reaktioner av grundläggande betydelse för utveckling av allergiska reaktioner. 
Även hos patienter med näspolypos förefaller aktiverade neutrofiler vara av betydelse. Dessa 
uppvisar ett ökat uttryck av CD11b samtidigt som ytepitelet uppvisar fler ICAM-1-molekyler. 
Dessa två molekyler interagerar och underlättar cell-cell-kontakt och bidrar till att indirekt 
driva på den inflammatoriska reaktionen. 
Sammanfattningsvis visar denna avhandling att receptoruttrycket på epitel och neutrofiler är 
förändrat vid sjukdomar som allergisk rinit och näspolypos. Detta leder i sin tur till ett förändrat 
immunologiskt svar och de resultat som presenteras i denna avhandling tyder på att detta kan 
bidra till dessa sjukdomars uppkomst och utveckling. 
 
  
 52 
ACKNOWLEDGEMENTS 
 
I would like to thank all the patients and healthy controls making the projects viable. Further, 
this thesis would not have been without help and support from many people. In particular, I 
would like to thank 
Lars Olaf Cardell, my main supervisor, for endless support and enthusiasm. I admire your 
philosophy on hard work but at the same time very permissive attitude, resulting in PhD 
students becoming independent researchers. Few colleagues have driven me as successfully as 
you have and I can not imagine a better supervisor than you. 
Susanna Kumlien Georén, my co-supervisor, for always being so positive, always believing 
in me and my capacity and for creating such a lovely milieu in the lab. I would not have made 
it without you as a co-supervisor and the group would not be the same without you and your 
skills in logistics. 
The lab, for its permissive atmosphere, stimulating lab-meetings with smart, hard-working 
colleagues and many laughter. Lotta Tengroth, co-author of Papers I-III - you were the perfect 
lab-partner to work with when I started in this group. Thank you for all your enthusiastic hard 
work, sanity, wisdom and courage. And, of course, thanks for dealing with me.  
Sandra Ekstedth, co-author of Paper IV, for your light headed mode, for your affection for 
neutrophils and for never feeling things are impossible. Cecilia Drakskog, co-author of Paper 
V, for all the hard work, for your flexibility, the sweets on your desk and all the nice times 
we’ve shared analyzing data. Eric Hjalmarsson, co-author of Paper IV, for your great 
knowledge on flow cytometry, for being so positive and, not to forget, for all your enthusiasm 
in training. Ronia Razawi, co-author of Paper I, for all the work with the co-cultures eventually 
leading to a publication in JACI. Finally, thanks to the rest of the group: Olivia Larsson (never 
saying no to proof reading), Yuan Xu, Nele De Klerk, Valteri Häyry, Magnus 
Starkhammar, Laila Hellkvist, Karin Jonstam and Åsa Kågedal. 
Co-authors Ola Winqvist, for learning me on the beauty of immunology and making it fun, 
fetching and sometimes fantastic and Claus Bachert, for helpful discussions, impressive 
knowledge on CRS and interesting meetings. 
To all the research nurses, in particular Maria Axelsson for logistics with patient samples and 
assisting me taking nasal biopsies from hundreds of healthy controls (always allowing 
uncomfortable hours - I could not have done it without you), Carina Israelsson, for all the 
help and for together with Maria, Karin and myself putting through the Dupilumab trial, and 
thanks to Eva Fransson and Carina Hedenström for skillfully assisting with patient samples.  
Previous and present Heads of the ENT-clinic Karolinska University Hospital:  
Mats Holmström (without your signature I would not have been in ‘Forskarskolan för 
kliniker’ 2012-2014), Bo Tideholm and Sushma Nordemar for all your support and 
encouragement, and to Rusana Bark, my present boss at the clinic, for believing in me and for 
successfully motivating me to work even harder. 
  53 
Present and former staff and colleagues at the ENT-department, Karolinska University 
Hospital, for your enthusiasm, support and teaching me surgery. Particularly thanks to the 
surgeons of the rhinology section and to the staff at the operating theatre for obtaining tissues 
during surgery - especially thanks to Hans Grudemo, Karin Toll and Karin Lundkvist. 
Rolf Uddman, for proof reading including adding spicy posts. Agneta Wittlock, for excellent 
and rapid administrative support.  
My long-lasting friends Julia Scheutz Nordmark, for skillfully drawing the cover picture of 
this thesis, Thea Palm, for helping me to rehears oral presentations and Maria Kugelberg, for 
being my mentor as a PhD student but also for being a mentor through life.  
Charlotta Zetterström, my mother, for inspiring me to become an MD, a surgeon and a 
researcher. Thank you for supporting me through the world of research and for teaching me to 
be fearless in life. My brother Erik Arebro, for proof reading manuscripts, always being there 
for me and for given me my lovely nephews David and Klas. My father, Urban Arebro, for 
endless support and attendance. My grandfather Rolf Zetterström, for the stimulating 
discussions on research we had that made me enter the world of science end eventually leading 
me to my main supervisor. Birgitta Zetterström-Karpe, my grandmother, for great 
inspiration. I can not count all the times I have glanced at your photo in the hall at Huddinge. 
To the rest of my great family, all my friends and all my beloved - I could probably not have 
done this without you in my life, or at least, it would have been a hundred times harder.  
 
 
This work was supported by grants from the Swedish Research Council, Karolinska 
Institutet, Karolinska University Hospital, the Hesselman’s Research Foundation, the Acta 
Oto-Laryngologica Foundation, the Nachmanssons Foundation, the Swedish Association for 
Otorhinolaryngology Head and Neck Surgery (SFOHH) and the European Rhinology 
Society (ERS). 
 
 
 
  55 
REFERENCES 
 
1. Fokkens WJ, Lund VJ, Mullol J, Bachert C, Alobid I, Baroody F, et al. European 
Position Paper on Rhinosinusitis and Nasal Polyps 2012. Rhinol Suppl 2012:3 p 
preceding table of contents, 1-298. 
2. Grossman J. One airway, one disease. Chest 1997; 111:11s-6s. 
3. Thorstensen WM, Sue-Chu M, Bugten V, Steinsvag SK. Nasal flow, volumes, and 
minimal cross sectional areas in asthmatics. Respir Med 2013; 107:1515-20. 
4. Promsopa C, Kansara S, Citardi MJ, Fakhri S, Porter P, Luong A. Prevalence of 
confirmed asthma varies in chronic rhinosinusitis subtypes. Int Forum Allergy Rhinol 
2016; 6:373-7. 
5. Jarvis D, Newson R, Lotvall J, Hastan D, Tomassen P, Keil T, et al. Asthma in adults 
and its association with chronic rhinosinusitis: the GA2LEN survey in Europe. Allergy 
2012; 67:91-8. 
6. Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A, et al. Allergic 
Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the 
World Health Organization, GA(2)LEN and AllerGen). Allergy 2008; 63 Suppl 86:8-
160. 
7. Okada H, Kuhn C, Feillet H, Bach JF. The 'hygiene hypothesis' for autoimmune and 
allergic diseases: an update. Clin Exp Immunol 2010; 160:1-9. 
8. Strachan DP. Hay fever, hygiene, and household size. Bmj 1989; 299:1259-60. 
9. Steinsvaag SK. Allergic rhinitis: an updated overview. Curr Allergy Asthma Rep 2012; 
12:99-103. 
10. Hellgren J, Cervin A, Nordling S, Bergman A, Cardell LO. Allergic rhinitis and the 
common cold--high cost to society. Allergy 2010; 65:776-83. 
11. Cardell LO, Olsson P, Andersson M, Welin KO, Svensson J, Tennvall GR, et al. 
TOTALL: high cost of allergic rhinitis-a national Swedish population-based 
questionnaire study. NPJ Prim Care Respir Med 2016; 26:15082. 
12. Jones NS, Carney AS, Davis A. The prevalence of allergic rhinosinusitis: a review. J 
Laryngol Otol 1998; 112:1019-30. 
13. Poetker DM, Mendolia-Loffredo S, Smith TL. Outcomes of endoscopic sinus surgery 
for chronic rhinosinusitis associated with sinonasal polyposis. Am J Rhinol 2007; 
21:84-8. 
14. Lee S, Lane AP. Chronic rhinosinusitis as a multifactorial inflammatory disorder. Curr 
Infect Dis Rep 2011; 13:159-68. 
15. Bachert C, Wagenmann M, Hauser U, Rudack C. IL-5 synthesis is upregulated in 
human nasal polyp tissue. J Allergy Clin Immunol 1997; 99:837-42. 
 56 
16. Van Zele T, Claeys S, Gevaert P, Van Maele G, Holtappels G, Van Cauwenberge P, et 
al. Differentiation of chronic sinus diseases by measurement of inflammatory 
mediators. Allergy 2006; 61:1280-9. 
17. Zhang N, Van Zele T, Perez-Novo C, Van Bruaene N, Holtappels G, DeRuyck N, et 
al. Different types of T-effector cells orchestrate mucosal inflammation in chronic sinus 
disease. J Allergy Clin Immunol 2008; 122:961-8. 
18. Bachert C, Zhang L, Gevaert P. Current and future treatment options for adult chronic 
rhinosinusitis: Focus on nasal polyposis. J Allergy Clin Immunol 2015; 136:1431-40; 
quiz 41. 
19. Tomassen P, Vandeplas G, Van Zele T, Cardell LO, Arebro J, Olze H, et al. 
Inflammatory endotypes of chronic rhinosinusitis based on cluster analysis of 
biomarkers. J Allergy Clin Immunol 2016; 137:1449-56.e4. 
20. Clark R, Kupper T. Old meets new: the interaction between innate and adaptive 
immunity. J Invest Dermatol 2005; 125:629-37. 
21. Pandey S, Agrawal DK. Immunobiology of Toll-like receptors: emerging trends. 
Immunol Cell Biol 2006; 84:333-41. 
22. Mansson A, Adner M, Cardell LO. Toll-like receptors in cellular subsets of human 
tonsil T cells: altered expression during recurrent tonsillitis. Respir Res 2006; 7:36. 
23. Mansson A, Adner M, Hockerfelt U, Cardell LO. A distinct Toll-like receptor 
repertoire in human tonsillar B cells, directly activated by PamCSK, R-837 and CpG-
2006 stimulation. Immunology 2006; 118:539-48. 
24. Mansson A, Cardell LO. Role of atopic status in Toll-like receptor (TLR)7- and TLR9-
mediated activation of human eosinophils. J Leukoc Biol 2009; 85:719-27. 
25. Fransson M, Benson M, Erjefalt JS, Jansson L, Uddman R, Bjornsson S, et al. 
Expression of Toll-like receptor 9 in nose, peripheral blood and bone marrow during 
symptomatic allergic rhinitis. Respir Res 2007; 8:17. 
26. Schleimer RP, Kato A, Kern R, Kuperman D, Avila PC. Epithelium: at the interface of 
innate and adaptive immune responses. J Allergy Clin Immunol 2007; 120:1279-84. 
27. Sha Q, Truong-Tran AQ, Plitt JR, Beck LA, Schleimer RP. Activation of airway 
epithelial cells by toll-like receptor agonists. Am J Respir Cell Mol Biol 2004; 31:358-
64. 
28. Lane AP, Truong-Tran QA, Myers A, Bickel C, Schleimer RP. Serum amyloid A, 
properdin, complement 3, and toll-like receptors are expressed locally in human 
sinonasal tissue. Am J Rhinol 2006; 20:117-23. 
29. Claeys S, de Belder T, Holtappels G, Gevaert P, Verhasselt B, van Cauwenberge P, et 
al. Human beta-defensins and toll-like receptors in the upper airway. Allergy 2003; 
58:748-53. 
  57 
30. Shin SH, Lee SH, Jeong HS, Kita H. The effect of nasal polyp epithelial cells on 
eosinophil activation. Laryngoscope 2003; 113:1374-7. 
31. Watanabe K, Shirasaki H, Kanaizumi E, Himi T. Effects of glucocorticoids on 
infiltrating cells and epithelial cells of nasal polyps. Ann Otol Rhinol Laryngol 2004; 
113:465-73. 
32. Schaefer D, Meyer JE, Pods R, Pethe W, Hedderich J, Schmidt C, et al. Endothelial 
and epithelial expression of eotaxin-2 (CCL24) in nasal polyps. Int Arch Allergy 
Immunol 2006; 140:205-14. 
33. Basinski TM, Holzmann D, Eiwegger T, Zimmermann M, Klunker S, Meyer N, et al. 
Dual nature of T cell-epithelium interaction in chronic rhinosinusitis. J Allergy Clin 
Immunol 2009; 124:74-80.e1-8. 
34. Vannella KM, Ramalingam TR, Borthwick LA, Barron L, Hart KM, Thompson RW, 
et al. Combinatorial targeting of TSLP, IL-25, and IL-33 in type 2 cytokine-driven 
inflammation and fibrosis. Sci Transl Med 2016; 8:337ra65. 
35. Mulder DJ, Pooni A, Mak N, Hurlbut DJ, Basta S, Justinich CJ. Antigen presentation 
and MHC class II expression by human esophageal epithelial cells: role in eosinophilic 
esophagitis. Am J Pathol 2011; 178:744-53. 
36. Dotan I, Allez M, Nakazawa A, Brimnes J, Schulder-Katz M, Mayer L. Intestinal 
epithelial cells from inflammatory bowel disease patients preferentially stimulate 
CD4+ T cells to proliferate and secrete interferon-gamma. Am J Physiol Gastrointest 
Liver Physiol 2007; 292:8. 
37. Goldwich A, Burkard M, Olke M, Daniel C, Amann K, Hugo C, et al. Podocytes are 
nonhematopoietic professional antigen-presenting cells. J Am Soc Nephrol 2013; 
24:906-16. 
38. Harries MJ, Meyer K, Chaudhry I, J EK, Poblet E, Griffiths CE, et al. Lichen 
planopilaris is characterized by immune privilege collapse of the hair follicle's 
epithelial stem cell niche. J Pathol 2013; 231:236-47. 
39. Takizawa R, Pawankar R, Yamagishi S, Takenaka H, Yagi T. Increased expression of 
HLA-DR and CD86 in nasal epithelial cells in allergic rhinitics: antigen presentation to 
T cells and up-regulation by diesel exhaust particles. Clin Exp Allergy 2007; 37:420-
33. 
40. Gereke M, Jung S, Buer J, Bruder D. Alveolar type II epithelial cells present antigen to 
CD4(+) T cells and induce Foxp3(+) regulatory T cells. Am J Respir Crit Care Med 
2009; 179:344-55. 
41. Lane AP, Saatian B, Yu XY, Spannhake EW. mRNA for genes associated with antigen 
presentation are expressed by human middle meatal epithelial cells in culture. 
Laryngoscope 2004; 114:1827-32. 
42. Curman B, Kampe O, Rask L, Peterson PA. Presence of alloreactive Ia antigens on 
murine intestine epithelial cells. Scand J Immunol 1979; 10:11-5. 
 58 
43. Kalb TH, Chuang MT, Marom Z, Mayer L. Evidence for accessory cell function by 
class II MHC antigen-expressing airway epithelial cells. Am J Respir Cell Mol Biol 
1991; 4:320-9. 
44. Kolaczkowska E, Kubes P. Neutrophil recruitment and function in health and 
inflammation. Nat Rev Immunol 2013; 13:159-75. 
45. Pillay J, Kamp VM, van Hoffen E, Visser T, Tak T, Lammers JW, et al. A subset of 
neutrophils in human systemic inflammation inhibits T cell responses through Mac-1. 
J Clin Invest 2012; 122:327-36. 
46. Kamp VM, Pillay J, Lammers JW, Pickkers P, Ulfman LH, Koenderman L. Human 
suppressive neutrophils CD16bright/CD62Ldim exhibit decreased adhesion. J Leukoc 
Biol 2012; 92:1011-20. 
47. Fransson M, Benson M, Wennergren G, Cardell LO. A role for neutrophils in 
intermittent allergic rhinitis. Acta Otolaryngol 2004; 124:616-20. 
48. Varney VA, Jacobson MR, Sudderick RM, Robinson DS, Irani AM, Schwartz LB, et 
al. Immunohistology of the nasal mucosa following allergen-induced rhinitis. 
Identification of activated T lymphocytes, eosinophils, and neutrophils. Am Rev Respir 
Dis 1992; 146:170-6. 
49. Fransson M, Adner M, Erjefalt J, Jansson L, Uddman R, Cardell LO. Up-regulation of 
Toll-like receptors 2, 3 and 4 in allergic rhinitis. Respir Res 2005; 6:100. 
50. Horak F. VTX-1463, a novel TLR8 agonist for the treatment of allergic rhinitis. Expert 
Opin Investig Drugs 2011; 20:981-6. 
51. Zhao CY, Wang X, Liu M, Jin DJ. Microarray gene analysis of Toll-like receptor 
signaling elements in chronic rhinosinusitis with nasal polyps. Int Arch Allergy 
Immunol 2011; 156:297-304. 
52. Lane AP, Truong-Tran QA, Schleimer RP. Altered expression of genes associated with 
innate immunity and inflammation in recalcitrant rhinosinusitis with polyps. Am J 
Rhinol 2006; 20:138-44. 
53. Zhu X, Zhu D, Dong Z, Sun K. [Expression of TLR9 in human nasal epithelial cells]. 
Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 2008; 22:356-8. 
54. Tengroth L, Millrud CR, Kvarnhammar AM, Kumlien Georen S, Latif L, Cardell LO. 
Functional effects of Toll-like receptor (TLR)3, 7, 9, RIG-I and MDA-5 stimulation in 
nasal epithelial cells. PLoS One 2014; 9:e98239. 
55. Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, Sanjo H, et al. A Toll-like receptor 
recognizes bacterial DNA. Nature 2000; 408:740-5. 
56. Klinman DM. Immunotherapeutic uses of CpG oligodeoxynucleotides. Nat Rev 
Immunol 2004; 4:249-58. 
  59 
57. Huminiecki L, Goldovsky L, Freilich S, Moustakas A, Ouzounis C, Heldin CH. 
Emergence, development and diversification of the TGF-beta signalling pathway 
within the animal kingdom. BMC Evol Biol 2009; 9:28. 
58. Aubert JD, Dalal BI, Bai TR, Roberts CR, Hayashi S, Hogg JC. Transforming growth 
factor beta 1 gene expression in human airways. Thorax 1994; 49:225-32. 
59. Watanabe R. Activin receptor-like kinase and the insulin gene. Vitam Horm 2011; 
85:1-27. 
60. Xia Y, Schneyer AL. The biology of activin: recent advances in structure, regulation 
and function. J Endocrinol 2009; 202:1-12. 
61. Schmierer B, Hill CS. TGFbeta-SMAD signal transduction: molecular specificity and 
functional flexibility. Nat Rev Mol Cell Biol 2007; 8:970-82. 
62. Sebald W, Nickel J, Zhang JL, Mueller TD. Molecular recognition in bone 
morphogenetic protein (BMP)/receptor interaction. Biol Chem 2004; 385:697-710. 
63. Verhamme FM, Bracke KR, Joos GF, Brusselle GG. Transforming growth factor-beta 
superfamily in obstructive lung diseases. more suspects than TGF-beta alone. Am J 
Respir Cell Mol Biol 2015; 52:653-62. 
64. Boxall C, Holgate ST, Davies DE. The contribution of transforming growth factor-beta 
and epidermal growth factor signalling to airway remodelling in chronic asthma. Eur 
Respir J 2006; 27:208-29. 
65. Antunes MB, Woodworth BA, Bhargave G, Xiong G, Aguilar JL, Ratner AJ, et al. 
Murine nasal septa for respiratory epithelial air-liquid interface cultures. Biotechniques 
2007; 43:195-6. 
66. Framson PE, Cho DH, Lee LY, Hershberg RM. Polarized expression and function of 
the costimulatory molecule CD58 on human intestinal epithelial cells. 
Gastroenterology 1999; 116:1054-62. 
67. Nakazawa A, Watanabe M, Kanai T, Yajima T, Yamazaki M, Ogata H, et al. Functional 
expression of costimulatory molecule CD86 on epithelial cells in the inflamed colonic 
mucosa. Gastroenterology 1999; 117:536-45. 
68. Lauriello M, Micera A, Muzi P, Di Rienzo Businco L, Bonini S. TLR4 and TLR9 
Expression in Different Phenotypes of Rhinitis. Int J Otolaryngol 2012; 2012:925164. 
69. Van Bruaene N, Derycke L, Perez-Novo CA, Gevaert P, Holtappels G, De Ruyck N, 
et al. TGF-beta signaling and collagen deposition in chronic rhinosinusitis. J Allergy 
Clin Immunol 2009; 124:253-9, 9.e1-2. 
70. Kariyawasam HH, Pegorier S, Barkans J, Xanthou G, Aizen M, Ying S, et al. Activin 
and transforming growth factor-beta signaling pathways are activated after allergen 
challenge in mild asthma. J Allergy Clin Immunol 2009; 124:454-62. 
71. Marzio R, Mauel J, Betz-Corradin S. CD69 and regulation of the immune function. 
Immunopharmacol Immunotoxicol 1999; 21:565-82. 
 60 
72. Estess P, DeGrendele HC, Pascual V, Siegelman MH. Functional activation of 
lymphocyte CD44 in peripheral blood is a marker of autoimmune disease activity. J 
Clin Invest 1998; 102:1173-82. 
73. Kambayashi T, Laufer TM. Atypical MHC class II-expressing antigen-presenting cells: 
can anything replace a dendritic cell? Nat Rev Immunol 2014; 14:719-30. 
74. Kadowaki N, Antonenko S, Liu YJ. Distinct CpG DNA and polyinosinic-polycytidylic 
acid double-stranded RNA, respectively, stimulate CD11c- type 2 dendritic cell 
precursors and CD11c+ dendritic cells to produce type I IFN. J Immunol 2001; 
166:2291-5. 
75. Hartmann G, Weiner GJ, Krieg AM. CpG DNA: a potent signal for growth, activation, 
and maturation of human dendritic cells. Proc Natl Acad Sci U S A 1999; 96:9305-10. 
76. Tan L, Rogers TJ, Hatzirodos N, Baker LM, Ooi E, Wormald PJ. Immunomodulatory 
effect of cytosine-phosphate-guanosine (CpG)-oligonucleotides in nonasthmatic 
chronic rhinosinusitis: an explant model. Am J Rhinol Allergy 2009; 23:123-9. 
77. Kodama S, Abe N, Hirano T, Suzuki M. Safety and efficacy of nasal application of 
CpG oligodeoxynucleotide as a mucosal adjuvant. Laryngoscope 2006; 116:331-5. 
78. Norlander T, Westrin KM, Fukami M, Stierna P, Carlsoo B. Experimentally induced 
polyps in the sinus mucosa: a structural analysis of the initial stages. Laryngoscope 
1996; 106:196-203. 
79. Yamazaki Y, Morita T. Molecular and functional diversity of vascular endothelial 
growth factors. Mol Divers 2006; 10:515-27. 
80. Lee HS, Myers A, Kim J. Vascular endothelial growth factor drives autocrine epithelial 
cell proliferation and survival in chronic rhinosinusitis with nasal polyposis. Am J 
Respir Crit Care Med 2009; 180:1056-67. 
81. Park SK, Kim HI, Yang YI. Roles of vascular endothelial growth factor, Angiopoietin 
1, and Angiopoietin 2 in nasal polyp. Laryngoscope 2009; 119:409-13. 
82. Watelet JB, Claeys C, Perez-Novo C, Gevaert P, Van Cauwenberge P, Bachert C. 
Transforming growth factor beta1 in nasal remodeling: differences between chronic 
rhinosinusitis and nasal polyposis. Am J Rhinol 2004; 18:267-72. 
83. Yang Y, Zhang N, Crombruggen KV, Lan F, Hu G, Hong S, et al. Differential 
Expression and Release of Activin A and Follistatin in Chronic Rhinosinusitis with and 
without Nasal Polyps. PLoS One 2015; 10:e0128564. 
84. Sauce D, Dong Y, Campillo-Gimenez L, Casulli S, Bayard C, Autran B, et al. Reduced 
Oxidative Burst by Primed Neutrophils in the Elderly Individuals Is Associated With 
Increased Levels of the CD16bright/CD62Ldim Immunosuppressive Subset. J 
Gerontol A Biol Sci Med Sci 2017; 72:163-72. 
85. Hao S, Andersen M, Yu H. Detection of immune suppressive neutrophils in peripheral 
blood samples of cancer patients. Am J Blood Res 2013; 3:239-45. 
  61 
86. Monteseirin J, Chacon P, Vega A, Sanchez-Monteseirin H, Asturias JA, Martinez A, 
et al. L-selectin expression on neutrophils from allergic patients. Clin Exp Allergy 
2005; 35:1204-13. 
87. Kinhult J, Egesten A, Benson M, Uddman R, Cardell LO. Increased expression of 
surface activation markers on neutrophils following migration into the nasal lumen. 
Clin Exp Allergy 2003; 33:1141-6. 
88. Fokkens WJ, Broekhuis-Fluitsma DM, Rijntjes E, Vroom TM, Hoefsmit EC. 
Langerhans cells in nasal mucosa of patients with grass pollen allergy. Immunobiology 
1991; 182:135-42. 
89. Godthelp T, Fokkens WJ, Kleinjan A, Holm AF, Mulder PG, Prens EP, et al. Antigen 
presenting cells in the nasal mucosa of patients with allergic rhinitis during allergen 
provocation. Clin Exp Allergy 1996; 26:677-88. 
90. Debbabi H, Ghosh S, Kamath AB, Alt J, Demello DE, Dunsmore S, et al. Primary type 
II alveolar epithelial cells present microbial antigens to antigen-specific CD4+ T cells. 
Am J Physiol Lung Cell Mol Physiol 2005; 289:15. 
91. Josset L, Menachery VD, Gralinski LE, Agnihothram S, Sova P, Carter VS, et al. Cell 
host response to infection with novel human coronavirus EMC predicts potential 
antivirals and important differences with SARS coronavirus. MBio 2013; 4:00165-13. 
92. Renkonen J, Mattila P, Lehti S, Makinen J, Sormunen R, Tervo T, et al. Birch pollen 
allergen Bet v 1 binds to and is transported through conjunctival epithelium in allergic 
patients. Allergy 2009; 64:868-75. 
93. Millrud CR, Mansson Kvarnhammar A, Uddman R, Bjornsson S, Riesbeck K, Cardell 
LO. The activation pattern of blood leukocytes in head and neck squamous cell 
carcinoma is correlated to survival. PLoS One 2012; 7:10. 
94. Millrud CR, Kagedal A, Kumlien Georen S, Winqvist O, Uddman R, Razavi R, et al. 
NET-producing CD16high CD62Ldim neutrophils migrate to tumor sites and predict 
improved survival in patients with HNSCC. Int J Cancer 2017. 
95. Broide D, Sriramarao P. Eosinophil trafficking to sites of allergic inflammation. 
Immunol Rev 2001; 179:163-72. 
96. Rothenberg ME. Eosinophilia. N Engl J Med 1998; 338:1592-600. 
97. Nish WA, Charlesworth EN, Davis TL, Whisman BA, Valtier S, Charlesworth MG, et 
al. The effect of immunotherapy on the cutaneous late phase response to antigen. J 
Allergy Clin Immunol 1994; 93:484-93. 
98. Nouri-Aria KT, Pilette C, Jacobson MR, Watanabe H, Durham SR. IL-9 and c-Kit+ 
mast cells in allergic rhinitis during seasonal allergen exposure: effect of 
immunotherapy. J Allergy Clin Immunol 2005; 116:73-9. 
99. Durham SR, Ying S, Varney VA, Jacobson MR, Sudderick RM, Mackay IS, et al. 
Cytokine messenger RNA expression for IL-3, IL-4, IL-5, and 
 62 
granulocyte/macrophage-colony-stimulating factor in the nasal mucosa after local 
allergen provocation: relationship to tissue eosinophilia. J Immunol 1992; 148:2390-4. 
100. Stephenson MF, Mfuna L, Dowd SE, Wolcott RD, Barbeau J, Poisson M, et al. 
Molecular characterization of the polymicrobial flora in chronic rhinosinusitis. J 
Otolaryngol Head Neck Surg 2010; 39:182-7. 
101. Perez Novo CA, Jedrzejczak-Czechowicz M, Lewandowska-Polak A, Claeys C, 
Holtappels G, Van Cauwenberge P, et al. T cell inflammatory response, Foxp3 and 
TNFRS18-L regulation of peripheral blood mononuclear cells from patients with nasal 
polyps-asthma after staphylococcal superantigen stimulation. Clin Exp Allergy 2010; 
40:1323-32. 
102. Patou J, Gevaert P, Van Zele T, Holtappels G, van Cauwenberge P, Bachert C. 
Staphylococcus aureus enterotoxin B, protein A, and lipoteichoic acid stimulations in 
nasal polyps. J Allergy Clin Immunol 2008; 121:110-5. 
103. Conley DB, Tripathi A, Seiberling KA, Schleimer RP, Suh LA, Harris K, et al. 
Superantigens and chronic rhinosinusitis: skewing of T-cell receptor V beta-
distributions in polyp-derived CD4+ and CD8+ T cells. Am J Rhinol 2006; 20:534-9. 
104. Bachert C, Hamilos DL. Are Antibiotics Useful for Chronic Rhinosinusitis? J Allergy 
Clin Immunol Pract 2016; 4:629-38. 
105. Anderson M, Stokken J, Sanford T, Aurora R, Sindwani R. A systematic review of the 
sinonasal microbiome in chronic rhinosinusitis. Am J Rhinol Allergy 2016; 30:161-6. 
106. Norlander T, Fukami M, Westrin KM, Stierna P, Carlsoo B. Formation of mucosal 
polyps in the nasal and maxillary sinus cavities by infection. Otolaryngol Head Neck 
Surg 1993; 109:522-9. 
107. Birk R, Aderhold C, Hormann K, Wenzel A, Kramer B, Eschenhagen T, et al. CpG-
Oligodeoxynucleotides in Chronic Rhinosinusitis Cell Culture. In Vivo 2016; 30:47-
52. 
108. Eguiluz-Gracia I, Bosco A, Dollner R, Melum GR, Lexberg MH, Jones AC, et al. Rapid 
recruitment of CD14 monocytes in experimentally induced allergic rhinitis in human 
subjects. J Allergy Clin Immunol 2016. 
109. Thelemann C, Eren RO, Coutaz M, Brasseit J, Bouzourene H, Rosa M, et al. Interferon-
gamma induces expression of MHC class II on intestinal epithelial cells and protects 
mice from colitis. PLoS One 2014; 9:e86844. 
110. Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids--new mechanisms 
for old drugs. N Engl J Med 2005; 353:1711-23. 
111. Van Zele T, Gevaert P, Holtappels G, Beule A, Wormald PJ, Mayr S, et al. Oral steroids 
and doxycycline: two different approaches to treat nasal polyps. J Allergy Clin 
Immunol 2010; 125:1069-76.e4. 
112. Passalacqua G, Albano M, Riccio A, Fregonese L, Puccinelli P, Parmiani S, et al. 
Clinical and immunologic effects of a rush sublingual immunotherapy to Parietaria 
  63 
species: A double-blind, placebo-controlled trial. J Allergy Clin Immunol 1999; 
104:964-8. 
113. Shamji MH, Durham SR. Mechanisms of immunotherapy to aeroallergens. Clin Exp 
Allergy 2011; 41:1235-46. 
114. Eberhardson M, Karlen P, Linton L, Jones P, Lindberg A, Kostalla MJ, et al. 
Randomised, Double-blind, Placebo-controlled Trial of CCR9-targeted Leukapheresis 
Treatment of Ulcerative Colitis Patients. J Crohns Colitis 2016. 
 
 
